СПОСОБ ОБЛИТЕРАЦИИ ВАРИКОЗНЫХ ВЕН НИЖНИХ КОНЕЧНОСТЕЙ

Изобретение относится к медицине, а именно к сосудистой хирургии. Производят пункцию магистрального ствола целевой подкожной вены в области бедра и в ее просвет заводят клеевой катетер. Далее производят пункцию магистрального ствола целевой подкожной вены в области голени и в ее просвет вводят катетер. Осуществляют цианакрилатную облитерацию целевой подкожной вены на бедре, для чего по мере выведения катетера в дистальном направлении производят введение клея, блокируя распространение ретроградного кровотока в целевой подкожной вене в пределах бедра. Затем по мере удаления катетера, установленного в магистральном стволе целевой вены на голени, в ее просвет вводят пенный склерозант до блокирования ретроградного кровотока в дистальном направлении. Способ позволяет снизить риск развития осложнений лечения варикозной болезни при сохранении высокой эффективности, снизить вероятность развития общей аллергической реакции за счет меньшего объема используемых для облитерации цианакрилата и склерозанта ...

ГЕМОСТАТИЧЕСКАЯ КОМПОЗИЦИЯ

Группа изобретений относится к области медицины, а именно к гемостатической композиции, содержащей волокна окисленной целлюлозы, имеющие распределение по размерам D90 менее 350 мкм и D50 менее 167 мкм, с концентрацией волокон в диапазоне 83,5-90,0 мас.% всей композиции, эпсилон-аминокапроновую кислоту (ε-ACA) с концентрацией в диапазоне 2,5-5,0 мас.% всей композиции, соль протамина с концентрацией в диапазоне 2,5-5,0 мас.% всей композиции, соль двухвалентного катиона, причем концентрация катиона указанной соли двухвалентного катиона составляет 1,3-1,8 мас.% всей композиции, при этом указанная соль двухвалентного катиона представляет собой хлорид кальция, при этом композиция пребывает в форме порошка и/или агрегатов, также относится к способу получения гемостатической композиции, также относится к способу образования геля, также относится к гемостатическому гелю и гемостатическому набору, относится к способу обработки кровоточащей раны, бактериальной инфекции в месте раны с минимизацией ...

Способ оперативного лечения эмпиемы плевры с бронхоплевральным свищом

Изобретение относится к медицине, а именно, к торакальной хирургии. Проводят торакоскопию для выявления локализации наружного отверстия бронхоплеврального свища. Затем осуществляют антисептическую обработку плевральной полости. Под контролем видеокамеры производят инъекции клеевой композиции в легочную ткань, окружающую свищевой ход. При этом в качестве клеевой композиции используют концентрированный мономер фибрина на основе собственной плазмы крови пациента в растворе карбонатно-бикарбонатного буфера-pH10. Инъекции клеевой композиции в легочную ткань осуществляют на 1-1,5 см глубже висцеральной плевры. Способ позволяет повысить эффективность обструкции хода бронхоплеврального свища, обеспечить надежный аэростаз, создать условия для купирования воспаления, обеспечить грануляционные процессы, улучшить эффективность пролиферации и репарации клеток повреждённых тканей по глубине свищевого хода. 1 з.п. ф-лы, 2 ил., 1 пр.

КОМПОЗИЦИЯ ДЛЯ ВОССТАНОВЛЕНИЯ ТВЕРДЫХ ТКАНЕЙ И НАБОР ДЛЯ ВОССТАНОВЛЕНИЯ ТВЕРДЫХ ТКАНЕЙ

Настоящее изобретение имеет отношение к композиции для восстановления твердых тканей, таких как губчатая кость, и набору для восстановления твердых тканей. Композиция для восстановления твердых тканей содержит 10-45 мас. частей мономера (А), который является мономером на основе (мет)акрилата, 54,9-80 мас. частей полимера (В), который является полимерным порошком на основе (мет)акрилата, 0,1-10 мас. частей инициатора полимеризации (С), который является органическим соединением бора, причем сумма компонентов (А)-(С) принимается равной 100 мас. частей, и 0,5-70 мас. частей контрастного вещества (X), которое является сульфатом бария или цирконием, имеющими средний по объему диаметр частиц 3-25,1 мкм. Набор для восстановления твердых тканей состоит из трех или более элементов, в котором каждый из компонентов вышеуказанной композиции разделены и содержатся в элементах в комбинации по выбору. Технический результат – получение композиции для восстановления твердых тканей и набора для восстановления ...

РАЗЛАГАЕМАЯ КРОВООСТАНАВЛИВАЮЩАЯ КОМПОЗИЦИЯ

СПОСОБ ЭМБОЛИЗАЦИИ АНЕВРИЗМ ГОЛОВНОГО МОЗГА ЖИДКОЙ КЛЕЕВОЙ КОМПОЗИЦИЕЙ

Изобретение относится к медицине, а именно к эндоваскулярной нейрохирургии. Выполняют пункцию левой или правой бедренной артерии. Затем на 0,035-0,038`` проводнике выполняют установку диагностического катетера в устье каротидных и позвоночных артерий. Осуществляют ангиографию каротидных и позвоночных артерий. Выявляют аневризму и осуществляют оценку анатомии и положения аневризмы относительно горизонтальной плоскости, оценку дистального кровотока интракраниальных сосудов. После чего выполняют смену диагностического катетера на баллон-окклюзирующий проводниковый катетер Corail+. Дополнительно через боковой канал системы в просвет сосуда капельно вводят гепаринизированный 0,9% раствор NaCl с нимодипином под контролем артериального давления в пределах 90/60-100/70 мм рт.ст. Затем проводят DMSO - совместимый микрокатетер с отделяемым кончиком 1,5 см Sonic и устанавливают в пришеечной части аневризмы. Выполняют суперселективную ангиографию через просвет микрокатетера. Раздувают баллон на конце ...

ХИТОЗАНОВЫЕ КОМПОЗИЦИИ

... 1. Ортопедическая композиция, содержащая пористые частицы хитозана, суспендированные в жидкой среде, где указанная жидкая среда дополнительно содержит биосовместимый полимер. 2. Ортопедическая композиция по п.1, где частицы имеют размер частиц от 10 мкм до 2 мм. 3. Ортопедическая композиция по п.1, где частицы состоят из смеси хитозана вместе с производными хитозана, полисахаридами и/или белками. 4. Ортопедическая композиция по п.3, где указанные производные выбраны из сульфатированного хитозана, N-карбоксиметилхитозана, O-карбоксиметилхитозана и N,О-карбоксиметилхитозана. 5. Ортопедическая композиция по п.1, где указанные частицы содержат по меньшей мере 50% хитозана. 6. Ортопедическая композиция по п.1, где указанные частицы содержат от 50 до 90% хитозана. 7. Ортопедическая композиция по п.1, где жидкая среда дополнительно содержит пластификатор. 8. Ортопедическая композиция по п.7, где пластификатор представляет собой глицерин. 9. Ортопедическая композиция по п.1, где биосовместимый ...

РАЗЛАГАЕМАЯ КРОВООСТАНАВЛИВАЮЩАЯ КОМПОЗИЦИЯ

ГЕМОСТАТИЧЕСКАЯ СМЕСЬ КОРОТКИХ И ДЛИННЫХ ВОЛОКОН НА ОСНОВЕ ЦЕЛЛЮЛОЗЫ

SPRÜHVORRICHTUNG ZUM AUFBRINGEN VON GEWEBEKLEBSTOFF

Implant

Implant

An implant 1 comprising a surface 32 engageable with a portion of at least one body part, preferably a bone 2, and attachable thereto be means of an adhesive that is preferably cured by means on an external energy source such as EM radiation, ultrasound energy or thermal energy; most preferably UV light. The implant 1 may also be provided with a conduit 4 through which the energy source may be introduced. A flange 30 extending around the periphery of the implant 1 and protruding towards the body is also taught. The flange 30 provides a stand-off between the surface 32 and the body when the implant 1 is in use, thereby controlling the thickness of adhesive in use. Also disclosed is a method of surgery comprising forming an implant 1, applying a layer of adhesive to a surface 32 of the implant 1 and engaging the surface 32 with a body part. It is also disclosed that the implant 1 may be shaped in accordance with data derived from the body part in 3D, preferably obtained using computer tomography ...

Wafer for an ostomy bag

A wafer for an ostomy bag 10, and an ostomy bag including said wafer and a pouch 6 (defined by two opposing surfaces of two walls) comprises a film 2 having an adhesive coating 1, wherein the adhesive comprises a composition comprising carboxymethyl cellulose (CMC) and a two-part addition-curing composition comprising silicone. The adhesive may be covered by a release liner, for example made from low density polyethylene (LDPE). The film may be attached to the pouch via an interfacial material 3 comprising of a low melting point co-polyamide (CoPA) layer 4 laminated with a polyethylene (PE) layer 5.

COMPOSITION AND PROCEDURE FOR THE ADJUSTMENT OF THE ADHESION OF CELLS AND BIO MOLECULES TO HYDROPHOBE SURFACES

PROCEDURE FOR THE PRODUCTION OF AUTO+LIED FIBRINKLEBERN

INJECT-CASH FIBRIN COMPOSITION FOR BONE REINFORCEMENT

IMPROVED BODY-ABSORBABLE OF BONE WAXES (III).

SPRAYING DEVICE FOR APPLYING FABRIC ADHESIVE

FORMABLE AND SETTABLE POLYMER BONE COMPOSITE AND METHOD OF PRODUCTION THEREOF

An ostomy appliance and an adhesive wafer for such appliance

The present invention concerns adhesive wafer for an ostomy appliance, said adhesive wafer being adapted for directly or indirectly securing an ostomy pouch to a person's skin, wherein the wafer comprises a starter hole surrounded by a plurality of cutting guidelines for enabling the person to cut the hole into a desired aperture size, wherein the cutting guidelines substantially converge with the starter hole at an upper region of the hole.

Porogen compositions, methods of making and uses

H:\grs\Intrwovn\NRPortbl\DCC\GRS54013_1.docx-16/10/2015 POROGEN COMPOSITIONS, METHODS OF MAKING AND USES The present specification discloses porogen compositions comprising a core material and shell material, methods of making such porogen compositions, methods of forming such porous materials using such porogen compositions, biocompatible implantable devices comprising such porous materials, and methods of making such biocompatible implantable devices. WO 2011/143213 PCT/US2011/035917 Under-fused and over-fused porogens Unill-ormly-fused: porogens ...

Therapeutic angiogenesis for treating erectile conditions

Disclosed are devices, methods and surgical procedures for detecting, imaging, analyzing, diagnosing and/or treating vascular disorders and related conditions of the human and mammalian body in males and/or females. In particular embodiments, treatments include methods for imaging, analyzing and improving erectile dysfunction and related conditions and potentially increasing angiogenesis in response to specifically diagnosed conditions.

Adhesives

FORMABLE AND SETTABLE POLYMER BONE COMPOSITE AND METHOD OF PRODUCTION THEREOF

A composite osteoimplant. The osteoimplant includes a polymer andbonederived particles. The composite is adapted and constructedto be formable during or immediately prior to implantation and tobe set after final surgical placement.

COMPOSITIONS AND METHODS FOR HEMOSTASIS

CROSSLINKED GELS COMPRISING POLYALKYLENEIMINES, AND THEIR USES AS MEDICAL DEVICES

One aspect of the present invention generally relates to methods of sealing a wound or tissue plane or filling a void splace. In a preferred embodiment, the wound is an ophthalmic, pleural or dural wound. In certain instances, the compositions used to seal the wound or tissue plane comprises a polyalkyleneimine. In a prefered embodiment, the polyalkyleneimine is polyethyleneimine. Treatment of the polyethyleneimine with a cross- linking reagent causes the polyethyleneimine polymers to polymerize forming a seal. In certain instances, the cross-linking reagent is a polyethylene glycol having reactive terminal groups. In certain instances, the reactive terminal groups are activated esters, such as N-hydroxy succinimide ester. In certain instances, the reactive terminal groups are isocyanates. In certain instances, the polyethyleneimine has a lysine, cysteine, isocysteine or other nucleophilic group attached to the periphery of the polymer. In certain instances, the polyethyleneimine is mixed ...

NERVE REPAIR WITH A HYDROGEL AND OPTIONAL ADHESIVE

The subject invention provides materials and methods for effective nerve repair. In a preferred embodiment, the subject invention provides nerve repair methods comprising the use of a fibrin glue and a polyethylene glycol (PEG) hydrogel to coapt severed nerve stumps or nerve grafts.

NERVE REPAIR WITH A HYDROGEL AND OPTIONAL ADHESIVE

The subject invention provides materials and methods for effective nerve repair. In a preferred embodiment, the subject invention provides nerve repair methods comprising the use of a fibrin glue and a polyethylene glycol (PEG) hydrogel to coapt severed nerve stumps or nerve grafts.

ANTIBACTERIAL MEDICINAL PRODUCT AND METHOD FOR PRODUCING SAME

The invention relates to a medicinal product, comprising an antibacterial hard material coating, which is applied to a main body and which comprises biocide. Said hard material coating includes at least one inner layer and one outer layer, wherein the biocide concentration in the outer layer is substantially constant and greater than the biocide concentration in the inner layer and the biocide concentration in the inner layer is greater than or equal to 0.2 at%.

IMPROVED METHOD OF TREATING PLEURAL EFFUSION

The present invention provides methods of treating pleural effusion in a subject, comprising removing fluid from the pleural space at an increased frequency, as compared to previous methods.

SKIN CONTACT MATERIAL

A substrate based skin contact material formed from a hydrocolloid having a silicone based component extending over regions of the substrate surface. The adhesive is formed non- continuously over the substrate to provide areas devoid of adhesive to allow appreciable moisture transfer between the skin and substrate and improve the skin friendliness of the material during use and allow convenient removal with avoidance of skin irritation.

SKIN CONTACT MATERIAL

A substrate based skin contact material formed from a hydrocolloid having a silicone based component extending over regions of the substrate surface. The adhesive is formed non- continuously over the substrate to provide areas devoid of adhesive to allow appreciable moisture transfer between the skin and substrate and improve the skin friendliness of the material during use and allow convenient removal with avoidance of skin irritation.

COMPOSITIONS AND METHODS FOR HEMOSTASIS

The present invention relates to water soluble and completely absorbable and/or physiologically degradable hemostatic compositions having a wax or wax-like base effective for use in tamponade hemostasis of bone or cartilage.

COMPOSITE MATERIAL HAVING ABSORBABLE AND NONABSORBABLE COMPONENTS

... 30,286 TITLE Composite Material Having Absorbable And Nonabsorbable Components The invention is a composite material of two or more biocompatible polymers, at least one of which is poly-tetrafluoroethylene (PTFE) and one of which is a bioabsorbable polymer. The nonabsorbable PTFE is used in the composite as a reinforcing binder. The reinforcing binder is a network of unsintered, interconnected micro-fibers which are formed, for example, by blending with a thermoplastic polymer vehicle, such as polymethylmethacrylate which is subsequently extracted. The bioabsorbable component is contained within the structure of the PTFE microfibrils. This composite is useful in the repair of mammalian tissue where tissue ingrowth and permanent support is required.

METHOD OF OBTAINING A GEL CARTILAGE REPAIR CARTILAGE, CHONDROCYTES COMPRISING CHITOSAN AND

THREE-DIMENSIONAL STRUCTURE COMPRISING PARTICLES OF CHITOSAN HYDROGEL

La présente invention concerne une structure tridimensionnelle formée de particules d'hydrogel physique de chitosane ou de dérivé de chitosane, associées à un polymère anionique, où lesdites particules d'hydrogel sont de taille moyenne comprise entre 10 µm et 1,5 mm. Le polymère anionique est de préférence de l'acide hyaluronique ou un dérivé d'acide hyaluronique ou un complexe d'acide hyaluronique. Cette structure peut être avantageusement utilisée pour ensemencer des cellules, notamment des chondrocytes, aux fins de prolifération et de synthèse de matrice extracellulaire. La structure est également appropriée pour une utilisation dans la réparation cartilagineuse ou pour une utilisation comme implant, ou comme greffe ou comme vecteur de principe actif chez l'homme ou l'animal.

produto

METHOD OF REMOVING MEDICAL ADHESIVE

Medical adhesive may be removed by applying a solution including tetrahydrofurfuryl acetate (THFA) to the surface upon which is located the adhesive and rubbing the surface to facilitate removal of the adhesive. The solution may be applied to a wipe before application to the surface and the wipe may be used to rub the surface. The surface may be living or dead human or animal skin, hard surfaces and medical instruments. Various additional ingredients may be added to the solution, like perfumes, emollients and other commonly known skin products and polymer diluents.

Method of removing medical adhesive

Medical adhesive may be removed by applying a solution including tetrahydrofurfuryl acetate (THFA) to the surface upon which is located the adhesive and rubbing the surface to facilitate removal of the adhesive. The solution may be applied to a wipe before application to the surface and the wipe may be used to rub the surface. The surface may be living or dead human or animal skin, hard surfaces and medical instruments. Various additional ingredients may be added to the solution, like perfumes, emollients and other commonly known skin products and polymer diluents.

Photo-crosslinked hydrogel material and preparation, composition, and application thereof photo-crosslinked hydrogel

This invention provides preparations, compositions, products, and applications of photo-crosslinked hydrogels. Component A—a photosensitive polymer derivative, component B—the photoinitiator, and auxiliary component C—other biocompatible polymer derivative each are respectively dissolved in a biocompatible medium to obtain solution A, solution B, and solution C. The solution A, the solution B, and the optional solution C are mixed homogenously to obtain a hydrogel precursor solution. The hydrogel precursor solution is subject to irradiation of the UV light for photocoupled crosslinking to form a photo-crosslinked hydrogel. The photo-crosslinked hydrogel exhibit rapid speed of photo-curing, strong tissue adhesion, excellent mechanical properties, good biocompatibility, and excellent clinical operability. In addition, this invention also provides a kit for making the photo-crosslinked hydrogel, and applications thereof in tissue engineering, regenerative medicine, 3D printing, and as a carrier ...

SYSTEM AND METHOD FOR PREPARING AUTOLOGOUS FIBRIN GLUE

PROBLEM TO BE SOLVED: To provide a system for preparing an autologous solid fibrin web suitable for regenerating a tissue in a living organism. SOLUTION: The system includes a sealed primary container containing a separation medium and a low-density high-viscosity liquid. The separation medium is capable of separating red blood cells from plasma when the container contains blood and is centrifuged, and the primary container has a first pressure. The system further includes a sealed secondary container containing a calcium-coagulation activator. The secondary container has a second pressure that is less than the first pressure. The system also comprises a transfer device including a cannula having a first end and a second end. The first and second ends are capable of puncturing the sealed primary and secondary containers in order to provide fluid communication between the primary and secondary containers. The low-density high-viscosity liquid of the primary container is capable of blocking ...

КОМПОЗИЦИИ ЧАСТИЧНО ДЕАЦЕТИЛИРОВАННЫХ ПРОИЗВОДНЫХ ХИТИНА

Изобретение относится к композициям, включающим биологически активные хитиновые олигомеры и их очищенные от эндотоксинов и частично деацетилированные хитиновые полимерные предшественники, и их применению в фармацевтических композициях для регенерации тканей, композициях с биоматериалами, медицинских приспособлениях и к процессам для получения упомянутых олигомеров. Способ извлечения высокоочищенного и полностью растворимого частично деацетилированного полимера хитина со степенью деацетилирования (СД) 30-60% включает этапы: нейтрализация частично деацетилированного хитина; растворение частично деацетилированного хитина в кислотном растворе; удаление нерастворившихся частиц с помощью последовательных этапов фильтрации; доведение рН раствора до величины выше 8; осаждение полностью растворенного и очищенного частично деацетилированного хитина в виде осадка путем повышения температуры и добавления соли, где осадок извлекают и промывают после осаждения путем фильтрования или центрифугирования ...

КОМПОЗИЦИИ И УСТРОЙСТВА ДЛЯ СКЛЕРОТЕРАПИИ С ПРИМЕНЕНИЕМ СВЕТООТВЕРЖДАЕМЫХ КЛЕЕВ

Группа изобретений относится к области медицины, а именно к флебологии, и предназначена для лечения заболеваний вен. Композиция для склеротерапии содержит фармацевтически приемлемый тканевой клей и склерозирующее лекарственное средство. При этом указанный фармацевтически приемлемый тканевой клей представляет собой инъекционный, светоотверждаемый или светоактивируемый, биологически разлагаемый и/или биологически совместимый клей. Клей представляет собой акрилат и указанный акрилат имеет период полувыведения в ткани, составляющий менее 2 лет. Также обеспечивается катетерное устройство для инъекций для введения указанной композиции, содержащее источник света, где клей и газ загружают в катетер и применяют при последующем болюсном введении. Катетерное устройство дополнительно содержит систему разделения. В других воплощениях представлены набор для склеротерапии, способ склеротерапии и применение светоотверждаемого клея в составе указанной композиции для лечения заболеваний вен. Использование ...

АНТИБАКТЕРИАЛЬНОЕ МЕДИЦИНСКОЕ ИЗДЕЛИЕ И СПОСОБ ЕГО ИЗГОТОВЛЕНИЯ

Группа изобретений относится к медицине. Описано медицинское изделие с нанесенным на основу антибактериальным покрытием из твердого материала с биоцидом. Это покрытие из твердого материала включает в себя по меньшей мере один внутренний слой и один наружный слой, при этом концентрация биоцида в наружном слое по существу постоянна и больше, чем концентрация биоцида во внутреннем слое, и концентрация биоцида во внутреннем слое больше или равна 0,2 ат.%. Покрытие обладает улучшенной адгезией к подложке. 2 н. и 7 з.п. ф-лы, 6 ил., 1 пр.

КОМПОЗИЦИЯ ДЛЯ ВОССТАНОВЛЕНИЯ ТВЕРДЫХ ТКАНЕЙ И НАБОР ДЛЯ ВОССТАНОВЛЕНИЯ ТВЕРДЫХ ТКАНЕЙ

Изобретение имеет отношение к композиции для восстановления твердых тканей, таких как губчатая кость, и набору для восстановления твердых тканей. Композиция для восстановления твердых тканей содержит: от 10 до 45 мас. частей мономера (А), который представляет собой мономер на основе (мет)акрилата; от 54,9 до 80 мас. частей полимерного порошка (В), который представляет собой полимерный порошок на основе (мет)акрилата, содержащий 54-95 мас.% полимерного порошка (b1), представляющего собой полимерный порошок на основе (мет)акрилата, имеющий среднеобъемный диаметр частиц от 27 до 80 мкм, причем удельная поверхность каждой частицы полимерного порошка (b1) составляет от 0,05 до 0,5 м2/г, при этом полимерный порошок (В) дополнительно содержит полимерный порошок (b2), имеющий удельную поверхность частиц от 0,51 до 1,2 м2/г, и/или полимерный порошок (b3), имеющий удельную поверхность частиц от 1,5 до 4,5 м2/г; от 0,1 до 10 мас. частей инициатора полимеризации (C), причем сумма компонентов (A)-(C ...

АДГЕЗИВНАЯ КОМПОЗИЦИЯ

Группа изобретений относится к области медицины, в частности, к адгезивной композиции для прикрепления адгезивного приспособления к коже, включающей (в % вес./вес.): 10-14% поли(этиленвинилацетата), 15-20% полипропиленгликоля, 13-18% сополимера пропилена и этилена, 10-15% полибутена, 1-5% воска, 4-8% полиакриловой кислоты и 20-40% одного или нескольких дополнительных материалов, поглощающих жидкость. Также предложены: адгезивное приспособление для прикрепления к поверхности кожи пользователя, содержащее вышеуказанную адгезивную композицию и по меньшей мере одно защитное покрытие, и применение такого приспособления для закрепления вокруг стомы. Группа изобретений обеспечивает адгезивную композицию, обладающую достаточным поглощением и когезией после поглощения, а также является формуемой для создания герметичного уплотнения вокруг стомы. 3 н. и 8 з.п. ф-лы, 2 табл.

Способ хирургического лечения осложненной язвы двенадцатиперстной кишки

Изобретение относится к медицине, хирургии. Доступ к осложненной язве двенадцатиперстной кишки с пенетрацией в поджелудочную железу выполняют путем дуоденотомии передней стенки. Ушитый кровоточащий сосуд язвы по шву обрабатывают клеем медицинским «Сульфакрилат». Параульцерально на расстоянии 1,5-2,0 см по здоровым тканям вводят 5 мл богатой тромбоцитами плазмы из аутокрови. Рассекают слизистую задней стенки ДПК вокруг патологического дефекта, отступая от края на 2-3 мм по здоровым тканям. Накладывают однорядные узловые швы на подслизистый слой, погружая зону язвенного дефекта и выводя его из просвета кишки. Восстанавливают слизистую однорядным узловым швом. Восстанавливают целостность передней стенки кишки. Способ позволяет снизить риск рубцовой деформации луковицы двенадцатиперстной кишки, снизить риск перфорации и кровотечения из язвенного дефекта, сохраняет анатомически правильное ориентирование двенадцатиперстной кишки, снижает риск острого панкреатита, связанного с травмой поджелудочной ...

Способ эмболизации желудка для лечения ожирения

Изобретение относится к медицине, а именно к рентгенэндоваскулярной хирургии. Вводят катетер в лучевую артерию. Под рентгеновским контролем определяют ветви левой желудочной артерии, которые снабжают часть желудка, отвечающую за выработку гормона грелина. Начинают введение эмболизирующих капсул диаметром 400-450 микрон с крайней верхней ветви артерии. Затем эмболизируют крайнюю нижнюю ветвь артерии, после этого последовательно эмболизируют средние ветви. При этом катетер вводят в каждую ветвь на глубину 4-6 мм. Способ обеспечивает повышение лечебного эффекта, снижение риска возникновения осложнений, за счет обеспечения более точного выявления ветвей желудочной артерии, сокращения площади ишемизации тканей, позволяет уменьшить вероятность возникновения болевого синдрома в верхних отделах живота, выраженности тошноты, уменьшает сроки пребывания в стационаре. 1 ил., 2 пр.

Способ полюсной клиновидной резекции селезенки

Изобретение относится к медицине, а именно к абдоминальной хирургии, и может быть использовано для выполнения органосберегающей операции при кистах, травматическом повреждении селезенки. Выполняют клиновидную резекцию верхнего или нижнего полюса селезенки под углом 45-60°. Восстановление анатомической целостности органа осуществляют путем использования сквозного П-образного шва при глубине резекции до 2 см или медицинского хирургического клея «Сульфакрилат» при резекции глубиной более 2 см. Накладывают на капсулу селезенки однорядный узловой микрохирургический шов под оптическим увеличением. Способ позволяет обеспечить сохранение селезенки, надежный гемостаз с минимальной травматизацией органа и точным послойным соприкосновением сшиваемых однородных слоев. 11 ил., 4 пр.

СПОСОБ ТИМПАНОПЛАСТИКИ

Изобретение относится к медицине, в частности к оториноларингологии. Производят хирургическое вмешательство на среднем ухе, включающее в себя использование на завершающем этапе операции средства воздействия на раневую поверхность. Средство воздействия на раневую поверхность выполняют в виде составной тампонады. При этом послойно укладывают от стенок наружного слухового прохода кнутри следующие материалы. Во-первых, силиконовые пластины толщиной 0,1 мм, причем одна из них покрывает передний меатотимпанальный угол, а другие 4-6 силиконовых пластин покрывают стенки костной части наружного слухового прохода. Во-вторых, биодеградируемый гидрогель «Аргакол» в объеме 1,0-1,5 мл, который наносят между силиконовыми пластинами и на них. В-третьих, 4-5 фрагментов губчатого материала «Merocel Medtronic», пропитанных биодеградируемым гидрогелем «Аргакол», заполняя им как передний меатотимпанальный угол, так и просвет костной части наружного слухового прохода. После чего выполняют тампонаду хрящевой ...

Способ абдоминопластики

Изобретение относится к медицине, а именно к пластической хирургии. Выполняют линейный поперечный кожно-подкожный разрез между передне-верхними остями подвздошных костей по краю роста волос лобковой зоны. Отслаивают кожно-подкожный лоскут тупым и острым путем до уровня мечевидного отростка и реберных дуг латерально до передней подмышечной линии справа и слева, за исключением области пупочного кольца. Ушивают медиальные края прямых мышц живота от мечевидного отростка до нижней трети гипогастральной области дубликатурой с использованием нити Тикрон 1. Затем выполняют послойное ушивание кожной раны, создают крестообразный разрез в области предполагаемого нео-пупа. Далее фиксируют края кожи пупа, край кожи передней брюшной стенки в зоне отверстия нео-пупа и апоневроза на 3, 6, 9 часах, захватывая апоневроз методом «снаружи-внутрь», оставляют нитки в ране. Выводят верхушку нео-пупа в рану, при этом, не подшивая ее к апоневрозу, затягивают нитки и погружают нео-пуп, формируя воронкообразное втяжение ...

СПОСОБЫ ЛЕЧЕНИЯ ДЕГЕНЕРАТИВНЫХ СОСТОЯНИЙ КОСТЕЙ

Изобретение относится к медицине. Описан способ лечения пациента с дегенеративными костями. Способ включает образование пустоты в локализованном участке дегенеративной кости и заполнениематериалом для регенерации костей, что приводит к образованию нового здорового естественного костного материала. Способ пригоден для улучшения качества кости в локализованном участке дегенеративной кости, такой как остеопенической или остеопорозной кости, путем улучшения минеральной плотности костей (BMD) вплоть до достижения по сути аналогичной BMD среднего здорового человека в возрасте пика BMD. 9 з.п. ф-лы, 34 ил., 9 табл., 3 пр.

ГЕМОСТАТИЧЕСКАЯ КОМПОЗИЦИЯ

Bone cement

BONE CEMENT.

COMPOSITIONS FOR TREATMENT AND RE-ESTABLISHMENT OF CARTILAGE DEFECTS WITH FUNCTIONAL BARRIER LAYER

Composition and method for regulating the adhesion of cells and biomolecules to hydrophobic surfaces

Therapeutic angiogenesis for treating erectile conditions

THERAPEUTIC ANGIOGENESIS FOR TREATING ERECTILE CONDITIONS Disclosed are devices, methods and surgical procedures for detecting, imaging, analyzing, diagnosing and/or treating vascular disorders and related conditions of the human and mammalian body in males and/or females. In particular embodiments, treatments include methods for imaging, analyzing and improving erectile dysfunction and related conditions and potentially increasing angiogenesis in response to specifically diagnosed conditions.

Bead composition for orthopaedic surgery and its manufacturing process

Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices

Semi-synthetic powder material, obtained by modifying the composition of a natural marine biomaterial, method for producing same, and applications thereof

The invention relates to a pulverulent semisynthetic material, derived from a natural marine biomaterial, namely the aragonitic inner layer of the shell of bivalve molluscs selected from the group comprising Pinctadines, notably Pinctada maxima, margaritifera, and Tridacnes, notably Tridacna gigas, maxima, derasa, tevaroa, squamosa, crocea, Hippopus hippopus, Hippopus porcelanus, in pulverulent form, with addition of insoluble and soluble biopolymers and calcium carbonate transformed by carbonation; it also relates to the method of preparation thereof and to the uses thereof.

METHOD OF REMOVING MEDICAL ADHESIVE

... ²²²Medical adhesive may be removed by applying a solution including ²tetrahydrofurfuryl acetate (THFA) to the surface upon which is located the ²adhesive and rubbing the surface to facilitate removal of the adhesive. The ²solution may be applied to a wipe before application to the surface and the ²wipe may be used to rub the surface. The surface may be living or dead human ²or animal skin, hard surfaces and medical instruments. Various additional ²ingredients may be added to the solution, like perfumes, emollients and other ²commonly known skin products and polymer diluents.² ...

SEMI-SYNTHETIC POWDER MATERIAL, OBTAINED BY MODIFYING THE COMPOSITION OF A NATURAL MARINE BIOMATERIAL, METHOD FOR PRODUCING SAME, AND APPLICATIONS THEREOF

L'invention porte sur un matériau semi-synthétique, pulvérulent, issu d'un biomatériau naturel marin qui est la couche aragonitique interne de la coquille de mollusques bivalves choisis dans le groupe comprenant des Pinctadines, notamment Pinctada maxima, margaritifera, et des Tridacnes, notamment Tridacna gigas,maxima, derasa, tevaroa, squamosa, crocea, Hippopus hippopus, Hippopus porcelanus, sous forme pulvérulente, additionné de bio-polymères insolubles et solubles et de carbonate de calcium transformé par carbonatation; elle porte également sur son procédé de préparation et sur ses utilisations.

NOVEL BIODEGRADABLE BONE PLATES AND BONDING SYSTEMS

The invention relates to novel internal fixation devices, such as bone plates, generally and novel craniomaxillofacial bone plates more specifically and systems for bonding the same. More specifically, the invention relates to bone plates made of a polymer blend of (poly)lactic acid and Ecoflex as well as a novel hot-melt adhesive polymer blend of the same material.

AN OSTOMY APPLIANCE AND AN ADHESIVE WAFER FOR SUCH APPLIANCE

The present invention concerns adhesive wafer for an ostomy appliance, said adhesive wafer being adapted for directly or indirectly securing an ostomy pouch to a person's skin, wherein the wafer comprises a starter hole surrounded by a plurality of cutting guidelines for enabling the person to cut the hole into a desired aperture size, wherein the cutting guidelines substantially converge with the starter hole at an upper region of the hole.

CROSSLINKED GELS COMPRISING POLYALKYLENEIMINES, AND THEIR USES AS MEDICAL DEVICES

One aspect of the present invention generally relates to methods of sealing a wound or tissue plane or filling a void splace. In a preferred embodiment, the wound is an ophthalmic, pleural or dural wound. In certain instances, the compositions used to seal the wound or tissue plane comprises a polyalkyleneimine. In a prefered embodiment, the polyalkyleneimine is polyethyleneimine. Treatment of the polyethyleneimine with a cross- linking reagent causes the polyethyleneimine polymers to polymerize forming a seal. In certain instances, the cross-linking reagent is a polyethylene glycol having reactive terminal groups. In certain instances, the reactive terminal groups are activated esters, such as N-hydroxy succinimide ester. In certain instances, the reactive terminal groups are isocyanates. In certain instances, the polyethyleneimine has a lysine, cysteine, isocysteine or other nucleophilic group attached to the periphery of the polymer. In certain instances, the polyethyleneimine is mixed ...

SYSTEMS AND METHODS FOR PREPARING AUTOLOGOUS FIBRIN GLUE

The invention provides a system for preparing an autologous solid-fibrin web suitable for regenerating tissue in a living organism. The system includes a sealed primary container containing a separation medium and a low-density high-viscosity liquid. The separation medium is capable of separating red blood cells from plasma when the container contains blood and is centrifuged, and the primary container has a first pressure. The system further includes a sealed secondary container containing a calcium-coagulation activator. The secondary container has a second pressure that is less than the first pressure. The system also comprises a transfer device including a cannula having a first end and a second end. The first and second ends are capable of puncturing the sealed primary and secondary containers in order to provide fluid communication between the first and second containers. The low-density high-viscosity liquid of the primary container is capable of blocking flow through the cannula ...

FORMABLE AND SETTABLE POLYMER BONE COMPOSITE AND METHOD OF PRODUCTION THEREOF

A composite osteoimplant. The osteoimplant includes a polymer andbonederived particles. The composite is adapted and constructedto be formable during or immediately prior to implantation and tobe set after final surgical placement.

Bio-adhesive agent comprising surface-modified hydroxyapatite and use thereof

The present invention relates to a bio-adhesive agent comprising a surface-modified hydroxyapatite and its use. More specifically, the present invention relates to a bio-adhesive agent for the adhesion between bone and bone, bone and tissue, bone and cartilage, or bone and tendon, or for the adhesion of a shield between bones or of an artificial joint, which comprises a surface-modified hydroxyapatite as an active ingredient, wherein the surface-modified hydroxyapatite is characterized in that a certain linker compound is covalently bonded to the surface of the hydroxyapatite; a method for coating the surface of a metal prosthesis using the surface-modified hydroxyapatite; and a metal prosthesis coated with the surface-modified hydroxyapatite obtained by said method.

MEDICAL TISSUE ADHESIVE AND PREPARATION METHOD THEREFOR

The invention provides a medical tissue adhesive and a preparation method thereof, belonging to the adhesive field. The medical tissue adhesive provided by the invention includes: a functional component, an assistant crosslinker and a dispersing agent, wherein the functional component is a polymer chain modified by tissue adhesive group or a micro nano particle modified by tissue-adhering functional groups, and the tissue-adhering functional groups includes: o-nitrobenzyl photoplate group, active ester group or carbonyl group. The medical tissue adhesive provided by the invention can not only use the dispersing agent to expel the tissue fluid or blood on the tissue surface, so that the adhesive molecular segment in the functional component can quickly form a chemical bond with the amino group on the tissue surface to form a strong tissue adhesive force, but also can trigger the adhesive molecular segment in the active ingredient to react with the amino group on the assistant crosslinker ...

БИОДЕГРАДИРУЕМЫЕ КОМПОЗИЦИИ, ИМЕЮЩИЕ ЧУВСТВИТЕЛЬНЫЕ К ДАВЛЕНИЮ АДГЕЗИВНЫЕ СВОЙСТВА

Изобретение относится к композиции для приклеивания материалов к биологической ткани. Композиция содержит продукт реакции (a) компонента, содержащего изоцианатную группу, выбранного из группы, состоящей из диизоцианата лизина и его сложных эфиров, триизоцианата лизина и его сложных эфиров и их комбинаций и (b) компонента, содержащего активную водородную группу, имеющую среднюю функциональность, равную, по меньшей мере, 2, выбранного из гидроксифункциональных соединений, выбранных из группы, состоящей из полимерных простых эфиров многоатомных спиртов, полимерных сложных эфиров многоатомных спиртов и гидроксиалькильных производных С-Суглеводородов и сахаридов, многофункциональных спиртов, выбранных из глицерина, диглицерина, эритрита, пентаэритрита, ксилита, арабита, фуцита, рибита, сорбита, маннита, гидроксиалкиламина, гидроксиалкильных производных С-С-карбоновых или дикарбоновых кислот и их комбинаций. Описаны также способ изготовления композиции, имеющей чувствительные к давлению адгезивные ...

ГЕМОСТАТИЧЕСКАЯ СМЕСЬ КОРОТКИХ И ДЛИННЫХ ВОЛОКОН НА ОСНОВЕ ЦЕЛЛЮЛОЗЫ

Изобретение имеет отношение к гемостатической композиции в форме волокон и/или агрегатов, способу получения такой композиции, способу достижения гемостаза, набору, способу обработки кровоточащей раны и применению гемостатической композиции в качестве бактерицидного агента, для остановки кровотечения, для герметизации, предотвращения спайкообразования и/или сведения к минимуму или предотвращения анастомозной утечки. Гемостатическая композиция в форме волокон и/или агрегатов содержит длинные и мелкие волокна на основе целлюлозы, причем длинные и мелкие волокна находятся в соотношении в диапазоне 5-25% масс. и 95-75% масс. соответственно общей массы композиции. Распределение по размерам для длинных волокон составляет: D90 от более 177 мкм до менее 350 мкм и D50 от более 95 мкм до менее 167 мкм, распределение по размерам для мелких волокон составляет: D90 менее 177 мкм и D50 менее 95 мкм. Способ получения гемостатической композиции содержит стадии: a) измельчение материала на основе целлюлозы ...

БИОСОВМЕСТИМЫЙ КОМПОНЕНТ

Настоящее изобретение относится к области биосовместимых компонентов, предназначенных для контакта с живыми клетками и тканью, в частности к имплантатам, предназначенным для имплантации в живую ткань. Биосовместимый компонент, предназначенный для имплантации в живую ткань, который имеет поверхность, предназначенную для контакта с живой тканью, отличается тем, что поверхность содержит частицы оксида металла, при этом указанные частицы имеют средний размер частиц менее 25 нм, при этом частицы имеют распределение по размеру частиц, полученное с помощью сканирующего измерителя подвижности частиц с электрораспылением (ES-SMPS), до 40%, при этом частицы образуют нанопористый слой и частицы равномерно распределены по всему указанному слою. Биосовместимый компонент может индуцировать раннее образование зародышей кристаллизации гидроксиапатита in vivo и тем самым способствовать остеоинтеграции имплантата. 2 н. и 34 з.п. ф-лы, 5 пр., 6 табл., 16 ил.

Устройство для доставки клея "Сульфакрилат" на линию степлерного шва и способ его использования

Группа изобретений относится к медицине, хирургии. Устройство включает в себя лапароскопический инструмент в виде трубки с ручками и рабочими браншами. В рабочем канале лапароскопического инструмента расположен полый катетер с павильоном для присоединения мандрена шприца с клеем «Сульфакрилат». Внутренний конец расположен между рабочими браншами инструмента и заканчивается торцевым отверстием. Устройство обеспечивает доставку клея «Сульфакрилат» на линию степлерного шва. При лапароскопических операциях через любой троакар вводят устройство для нанесения клея «Сульфакрилат». Браншами инструмента фиксируют линию шва. К павильону присоединяют шприц с клеем «Сульфакрилат». Доставку клея на линию шва осуществляют через установленный в просвет канала катетер. Клей вводят через катетер, продвигая его вдоль фиксированной браншами степлерной линии. Применение устройства повышает надежность операции с пересечением и сшиванием полых органов, снижает риск несостоятельности линии степлерного шва и кровотечения ...

ПОРОШКООБРАЗНЫЙ, ПОЛУСИНТЕТИЧЕСКИЙ МАТЕРИАЛ, ПОЛУЧЕННЫЙ ИЗМЕНЕНИЕМ СОСТАВА МОРСКОГО ПРИРОДНОГО БИОМАТЕРИАЛА, СПОСОБ ЕГО ПРОИЗВОДСТВА И ПРИМЕНЕНИЕ

Группа изобретений относится к области медицины, а именно к порошкообразному полусинтетическому материалу для изготовления заменителей кости, инъекционных цементов или цементов для герметизации эндопротезов или для изготовления устройств для биоабсорбируемого остеосинтеза и формованных имплантатов, полученному из морского природного биоматериала, с добавками нерастворимых и растворимых биополимеров и карбоната кальция, преобразованного карбонатизацией, где природный морской биоматериал представляет собой арагонитовый внутренний слой раковины двустворчатых моллюсков, выбранный из группы, включающей Pinctadines и Tricdacnes, а также относится к способу получения порошкообразного полусинтетического материала; к применению материала в качестве костного заменителя с приготовлением непосредственно перед применением для заживления или восстановления потерь вещества, лечения ожогов, струпьев, язв, эритемных кожных повреждений или для изготовления устройств или литых имплантатов; к применению карбоната ...

МЕДИЦИНСКИЙ КЛЕЙ

Изобретение относится к медицине, конкретно к разработке новых клеевых материалов для хирургии, способных обеспечить надежный гемо-, пневмо- и холестаз, герметичность раневых поверхностей при выполнении оперативных вмешательств на полых органах и паренхиматозных органах, в частности печени. Описан клей, который содержит полиоксипропропиленгликоль с молекулярной массой больше 3000, изоционатсодержащий компонент - 4,4-дифенилметандиизоционат, катализатор - оксипропилированный этилендиамин. Клей проявляет улучшенные адгезионные свойства, хорошую биосовместимость, гидрофильность, бактерицидные и гемостатические свойства, высокую герметичность анастомозов и хирургических швов при полостных операциях. 2 табл., 2 пр.

АНТИБАКТЕРИАЛЬНОЕ МЕДИЦИНСКОЕ ИЗДЕЛИЕ И СПОСОБ ЕГО ИЗГОТОВЛЕНИЯ

... 1. Медицинское изделие с нанесенным на основу (1) антибактериальным покрытием из твердого материала с биоцидом, включающим в себя по меньшей мере один внутренний слой (5) с толщиной d1 по меньшей мере 0,2 мкм и один наружный слой (9) с толщиной d2 по меньшей мере 0,5 мкм, при этом внутренний слой (5) расположен между наружным слоем (9) и основой (1), а наружный слой (9) содержит по существу постоянную по всей его толщине, усредненную по глубине по меньшей мере 20 нм концентрацию bcI биоцида, большую или равную 2 ат.%, отличающееся тем, что внутренний слой (5) имеет усредненную по глубине 20 нм концентрацию биоцида с максимальным значением bcII, большим или равным 0,2 ат.%, и концентрация биоцида внутреннего слоя (5) по всей его толщине меньше, чем по существу постоянная концентрация bcI биоцида наружного слоя (9).2. Медицинское изделие по п. 1, отличающееся тем, что между внутренним слоем (5) и основой (1) расположен по меньшей мере один адгезивный слой и/или защищающий от износа слой и ...

Способ одномоментной профилактики билиарного рефлюкса и протекции гастроэнтероанастомоза при выполнении минижелудочного шунтирования

Изобретение относится к медицине, хирургии и может быть использовано при лапароскопических операциях по коррекции морбидного ожирения, выполнении минижелудочного шунтирования. Выполняют прошивание линейным степлером в поперечном оси желудка направлении. Второе прошивание осуществляют картриджем линейного сшивающего аппарата перпендикулярно первому в продольном к оси желудка направлении. Затем по малой кривизне желудка вводят толстый зонд. Прошивание проводят параллельно зонду. Формируют отверстия на передней стенке дистального отдела малого желудочка и на участке тонкой кишки, Вводят бранши сшивающего аппарата и формируют линейный аппаратный гастроэнтероанастомоз. Приводящий отдел тонкой кишки подшивают одним узловым швом к латеральной стенке малого желудочка с захватом степлерной линии. На степлерную линию наносят 0,3 мл клея «Сульфакрилат». Следующие 0,3 мл клея наносят на линию непрерывного однорядного шва и 0,2 мл клея наносят на переднюю стенку антрального отдела. Отводящая петля тонкой ...

СПОСОБ ЭМБОЛИЗАЦИИ АНЕВРИЗМ ГОЛОВНОГО МОЗГА ЖИДКОЙ КЛЕЕВОЙ КОМПОЗИЦИЕЙ

Изобретение относится к медицине, а именно к эндоваскулярной нейрохирургии. Выполняют пункцию левой или правой бедренной артерии. Затем на 0,035-0,038`` проводнике выполняют установку диагностического катетера в устье каротидных и позвоночных артерий. Осуществляют ангиографию каротидных и позвоночных артерий. Выявляют аневризму и осуществляют оценку анатомии и положения аневризмы относительно горизонтальной плоскости, оценку дистального кровотока интракраниальных сосудов. После чего выполняют смену диагностического катетера на баллон-окклюзирующий проводниковый катетер Corail+. Дополнительно через боковой канал системы в просвет сосуда капельно вводят гепаринизированный 0,9% раствор NaCl с нимодипином под контролем артериального давления в пределах 90/60-100/70 мм рт.ст. Затем проводят DMSO - совместимый микрокатетер с отделяемым кончиком 1,5 см Sonic и устанавливают в пришеечной части аневризмы. Выполняют суперселективную ангиографию через просвет микрокатетера. Раздувают баллон на конце ...

АДГЕЗИВНАЯ КОМПОЗИЦИЯ ДЛЯ МЯГКИХ ТКАНЕЙ, АДГЕЗИВНАЯ КОМПОЗИЦИЯ ДЛЯ РАНЕВОЙ ПОВЯЗКИ ИЛИ КОМПОЗИЦИЯ РАНЕВОЙ ПОВЯЗКИ

... 1. Адгезивная композиция для мягких тканей, адгезивная композиция для раневой повязки или композиция раневой повязки, включающая мономер (А), полимерные частицы (В), имеющие средневесовой молекулярный вес 210000 или более и 1500000 или менее и среднеобъемный диаметр частиц 1,0 мкм или более и 90 мкм или менее, и композицию инициатора полимеризации (С), содержащую борорганическое соединение.2. Адгезивная композиция для мягких тканей, адгезивная композиция для раневой повязки или композиция раневой повязки по п.1, где полимерные частицы (В), по крайней мере, один тип, выбранный изполимерных частиц (В1), имеющих средневесовой молекулярный вес 1000000 или более и 1400000 или менее и среднеобъемный диаметр частиц 1,0 мкм или более и 90 мкм или менее,полимерных частиц (В2), имеющих средневесовой молекулярный вес 750000 или более и менее 1000000 и среднеобъемный диаметр частиц более 30 мкм и 90 мкм или менее,полимерных частиц (В3), имеющих средневесовой молекулярный вес 250000 или более и 950000 ...

GELWUNDVERBANDSZUSAMMENSETZUNGEN UND VERFAHREN ZU DEREN GEBRAUCH

ZUSAMMENSETZUNG UND VERFAHREN ZUR REGULIERUNG DER ADHÄSION VON ZELLEN UND BIOMOLEKÜLEN AN HYDROPHOBE OBERFLÄCHEN

GELWUNDVERBANDSZUSAMMENSETZUNGEN AND PROCEEDING TO THEIR USE

WOUND GEL COMPOSITIONS AND METHODS OF USING THEM

Cohesive demineralized bone compositions

Absorbable implants and methods for their use in hemostasis and in the treatment of osseous defects

Novel biodegradable bone plates and bonding systems

The invention relates to novel internal fixation devices, such as bone plates, generally and novel craniomaxillofacial bone plates more specifically and systems for bonding the same. More specifically, the invention relates to bone plates made of a polymer blend of (poly)lactic acid and Ecoflex as well as a novel hot-melt adhesive polymer blend of the same material.

Degradable haemostat composition

The present invention relates to a haemostat composition that is able to safely gradually and fully degrade in a human or animal body within about 30 days and so can be utilised by physicians to stem a flow of blood and promote healing both after as well as during surgical procedures.

BONE CEMENT

Semi-synthetic powder material, obtained by modifying the composition of a natural marine biomaterial, method for producing same, and applications thereof

The invention relates to a semi-synthetic powder material, derived from a natural marine biomaterial that is the inner aragonitic layer of the shell of bivalve molluscs chosen from the group comprising Pinctada, in particular Pinctada maxima and margaritifera, Tridacna, in particular Tridacna gigas, maxima, derasa, tevaroa, squamosa and crocea, Hippopus hippopus and Hippopus porcelanus, in powder form, supplemented with insoluble and soluble bio-polymers and calcium carbonate transformed by carbonation; it also relates to the method for preparing same and the uses thereof.

BREAST IMPLANT SPACERS FOR THE TREATMENT OF PERIPROSTHETIC BREAST IMPLANT INFECTIONS

The present disclosure provides improved devices and methods to treat periprostheticbreast implant infections.

NOVEL BIODEGRADABLE BONE PLATES AND BONDING SYSTEMS

The invention relates to novel internal fixation devices, such as bone plates, generally and novel craniomaxillofacial bone plates more specifically and systems for bonding the same. More specifically, the invention relates to bone plates made of a polymer blend of (poly)lactic acid and Ecoflex.TM. as well as a novel hot-melt adhesive polymer blend of the same material.

A DRAINABLE OSTOMY POUCH

The present invention concerns a drainable ostomy pouch comprising first proximal pouch wall and second distal pouch wall joined together along the outer periphery to form a cavity for accommodating waste material and to form an outlet portion with an outlet for draining the content of the pouch; an inlet provided in the first pouch wall for receiving waste into the pouch; a comfort layer provided at least on the distal side wall; a closure system with first and second fastener strips provided on at least one, preferably both exterior sides of the pouch walls for in cooperation to close the outlet by folding the outlet portion upon itself, wherein the second fastener strip is provided between the comfort layer and the distal side wall such that the outlet portion when folded up may be releasably secured to the comfort layer between the comfort layer and the distal side wall.

BIOCOMPATIBLE COMPONENT

The invention provides a biocompatible component having a surface intended for contact with living tissue, wherein the surface comprises particles of metal oxide, said particleshaving an average particle size of less than 100 nm. A method for the production of such biocompatible component is also provided. It was found that the bioactivity of the biocompatible component was increased compare to a reference in that it induced earlier apatite nucleation in vitro. It is believed that by the biocompatible component may induce early hydroxyapatite nucleation in vivo and thus promote osseointegration of an implant.

Blood coagulation inducing polymer hydrogel

The present application is drawn to a synthetic, polymer hydrogel-based material, which is able to actively induce the body's natural hemostatic coagulation process in blood or acellular plasma. The present invention provides the development of a primary amine containing polymer hydrogel capable of inducing blood coagulation and delivering therapeutics for hemostatic or wound care applications, and a method of forming such a primary amine containing polymer hydrogel capable of inducing the blood coagulation process. The primary amine containing polymer hydrogel is able to achieve the same end result as biological-based hemostatics, without the innate risk of disease transmission or immunological response, and at a fraction of the price. Furthermore, due to its inherent hydrogel-based design the material has the capability of arresting blood loss while simultaneously delivering therapeutics in a controlled manner, potentially revolutionizing the way in which wounds are treated.

Bone cement system for bone augmentation

A bone cement is provided that includes a solid component and a liquid component. The solid component and liquid component are mixed together to form the bone cement. After completion of the solid and liquid component mixing, the bone cement has an initial viscosity effective for manual application or manual injection onto or into a targeted anatomical location, e.g., bone, and the cement has stable viscosity range that over both time and temperature is effective for uniformly filling the targeted anatomical location, for example an osteoporotic bone or a fractured vertebral body, with minimal to no leakage of the cement from the targeted anatomical location. Additionally, both the initial viscosity and the stable viscosity of the bone cement are within a range that renders the bone cement effective for injection with a manually operated syringe or multiple syringes.

Fracture fixation systems

Systems for bone fracture repair are disclosed. One system includes a biocompatible putty that may be packed about a bone fracture to provide full loadbearing capabilities within days. The disclosed putties create an osteoconductive scaffold for bone regeneration and degrade over time to harmless 5 resorbable byproducts. Fixation devices for contacting an endosteal wall of an intramedullary (IM) canal of a fractured bone are also disclosed. One such fixation device includes a woven elongated structure fabricated from resorbable polymer filaments. The woven elongated structure has resilient properties that allow the woven 10 structure to be radially compressed and delivered to the IM canal using an insertion tube. When the insertion tube is removed, the woven structure expands towards its relaxed cross-sectional width to engage the endosteal wall. The woven elongated structure is impregnated with a resorbable polymer resin that cures in situ, or in the IM canal.

Bone cement composition, bone cement composition kit and forming method of bone cement hardened material

The invention has as its objects the provision of a bone cement composition, a bone cement composition kit for obtaining the bone cement composition, and a production method of a bone cement hardened material, which are short in doughing time that is a time required to become a state in which a good handling operation can be conducted, and have consequently capable of achieving a high working efficiency by shortening the time required before the handling operation is started. The bone cement composition of the invention contains large-diameter (meth)acrylate polymer particles having an average particle diameter of 10 to 60 μm, small-diameter (meth)acrylate polymer particles having an average particle diameter of 0.1 to 2.0 μm, a (meth)acrylate monomer and a polymerization initiator, wherein the content of the small-diameter (meth)acrylate polymer particles is 5 to 30% by mass based on the total mass of the small-diameter (meth)acrylate polymer particles and the large-diameter (meth)acrylate polymer particles.

Adhesive structure with stiff protrusions on adhesive surface

An adhesive structure is provided comprising a surface from which extend substantially cylindrical protrusions comprising a stiff resin having a Young's modulus of greater than 17 MPa. The protrusions are of sufficiently low diameter to promote adhesion by physical attractive forces, e.g., Van der Waals attractive forces, as measured by shear adhesion between the adhesive structure and a target surface. A method for preparing the structure is provided as well as a combination of the adhesive structure and target surface.

Absorbable adhesive paste

An absorbable adhesive paste contains absorbable solid carboxy-bearing microparticles dispersed in a continuous phase of an alkoxyalkyl cyanoacrylate. The paste may contain a soluble absorbable polymeric viscosity modifier and at least one bioactive agent to maximize the effective application as a cover for compromised tissues and wounds or as sealants, blocking agents, or hemostatic agents.

Degradable hemostatic sponge and extrusion system and method for manufacturing the same

A degradable hemostatic sponge that can be self-degraded and absorbed by a human body has poly lactic acid as its main material and mixed with a moisture-absorbent material, such as collagen, chitosan, starch and the like, at a specific ratio. Given grinding, mixing and melting steps, the materials using a supercritical fluid as a foaming agent can be used to manufacture the degradable hemostatic sponge having an open-cell microcellular form by a continuous extrusion foaming process. In addition, the present invention also includes a system and a method for manufacturing the degradable hemostatic sponge.

Antimicrobial adhesive system

An adhesive composition having dispersed therein a broad spectrum antimicrobial agent for use in medical applications, such as an adhesive for surgical drapes, wound dressings and tapes, is provided. The adhesive is composed of acrylic polymers, tackifiers and a preferred antimicrobial agent, diiodomethyl-p-tolylsulfone. The subject adhesive composition may be formulated as either an essentially solventless hot melt, or as a solvent based system wherein an emulsion of the antimicrobial agent and the removal of excess solvent is avoided.

Photochemical tissue bonding

Photochemical tissue bonding methods include the application of a photosensitizer to a tissue, e.g., cornea, followed by irradiation with electromagnetic energy to produce a tissue seal. The methods are useful for wound repair, or other tissue repair.

Osteoinductive bone graft injectable cement

Osteoconductive bone graft materials are provided. These compositions contain injectable cements and demineralized bone matrix fibers. The combination of these materials enables the filling of a bone void while balancing strength and resorption.

Porous vascular closure plug with starch powder

The disclosure provides a composite plug for vascular closure including a hemostatic material, and a method of manufacturing the composite plug including a hemostatic material. The composite plug may comprise one or more materials having varying porosity, density, or composition, and may include a powdered hemostatic material.

Composite bone cements with a pmma matrix, containing bioactive antibacterial glasses or glassceramics

A bone cement comprising an acrylic polymeric component and an inorganic component comprising a bioactive glass or glass-ceramic, comprising at least one metal oxide having an anti-bacterial activity, wherein said glass or glass-ceramic component is adapted to release ions of said metal in contact with physiological fluids. The bone cement performs a sustained antibacterial action, also promoting binding with the tissues with which it is contacted, and it is advantageously employed in the fixation of orthopaedic prostheses, in the production of temporary prostheses and in spinal surgery.

Preparation of bone cement compositions

A method for the preparation of injectable ready-to-use paste bone cement compositions by mixing a dry inorganic bone cement powder comprising a particulate calcium sulfate hemihydrate capable of hardening in vivo by hydration of the calcium sulfate hemihydrate forming calcium sulfate dihydrate, an aqueous liquid and an additive that normally retards the setting process, said method comprising a) providing a bone cement powder comprising calcium sulfate hemihydrate, an accelerator for the hardening of the calcium sulfate hemihydrate by hydration, said accelerator being selected from the group consisting of saline and calcium sulfate dihydrate, and a powdered calcium phosphate component b) mixing the bone cement powder with the aqueous liquid for a period of time c) leaving the mixture for the time needed for allowing the hydration reaction of the calcium sulfate hemihydrate to proceed and allowing calcium sulfate dihydrate crystals to form and grow, and d) admixing the additive by means of a short-duration mixing using a minimum of energy surprisingly shortens the setting times for the cement comprising the additive that retard the setting process to the level observed in the absence of the additive and enables a complete hydration of calcium sulfate hemihydrate to calcium sulfate dihydrate, even when using additives else preventing the hardening.

Compositions and methods for arthrodetic procedures

The present invention provides compositions and methods for facilitating fusion of bones in a joint. The present invention provides compositions and methods for promoting fusion of bones in arthrodetic procedures. In one embodiment, a method of performing an arthrodetic procedure comprises providing a composition comprising PDGF disposed in a biocompatible matrix and applying the composition to a site of desired bone fusion in a joint.

Reinforced surgical adhesives and sealants and their in-situ application

In situ application of reinforced adhesive: applying uncured and curable matter to a surface, applying biocompatible inert reinforcing agent comprising at least one curing agent to the uncured composition; allowing curing within subject, cured composition together with the added reinforcing agent being configured to have improved mechanical support and strength.

Reversible oral adhesive gel

The invention relates to a reversible oral adhesive gel. The reversible oral adhesive gel is suitable for application to lips to inhibit oral (mouth) breathing and to promote nasal breathing and thereby prevent or ameliorate snoring and to correct other respiratory problems.

Biocompatible component

The invention provides a biocompatible component having a surface intended for contact with living tissue, wherein the surface comprises particles of metal oxide, said particles having an average particle size of less than 100 nm. A method for the production of such biocompatible component is also provided. It was found that the bioactivity of the biocompatible component was increased compare to a reference in that it induced earlier apatite nucleation in vitro. It is believed that by the biocompatible component may induce early hydroxyapatite nucleation in vivo and thus promote osseointegration of an implant.

Hemostatic sponge

The present invention provides a hemostatic porous composite sponge comprising i) a matrix of a biomaterial and ii) one hydrophilic polymeric component comprising reactive groups wherein i) and ii) are associated with each other so that the reactivity of the polymeric component is retained, wherein associated means that—said polymeric component is coated onto a surface of said matrix of a biomaterial, or—said matrix is impregnated with said polymeric material, or—both.

Kit and method for producing bone cement

A kit for producing bone cement includes at least one paste A and one paste B. Paste A contains at least one monomer (a1) for radical polymerization; at least one polymer (a2) insoluble in monomer (a1); at least one polymer (a3) soluble in monomer (a1); and at least one radical polymerization initiator (a4). The weight ratio of the at least one polymer (a2) to the at least one polymer (a3) is at least 2 to 1. Paste B contains at least one monomer (b1) for radical polymerization; at least one polymer (b2) and at least one accelerator (b3) soluble in monomer (b1); and optionally a polymer (b4) insoluble in monomer (b 1 ). The maximum quantity of polymer (b4) is 5% by weight, relative to the total weight of paste B. The weight ratio of polymer (b4) to the at least one polymer (b2) is no more than 0.2.

Injectable, load-bearing cell/microbead/calcium phosphate bone paste for bone tissue engineering

The invention provides injectable, stem cell-containing calcium phosphate bone pastes for bone tissue engineering and methods of making and using the same.

Polysaccharide Based Hydrogels

Polysaccharide based hydrogel compositions and methods of making and using the same are provided. The subject polysaccharide based hydrogel compositions are prepared by combining a polysaccharide component with a hydrophilic polymer and a cross-linking agent. Also provided are kits and systems for use in preparing the subject compositions.

BIO-ADHESIVE AGENT COMPRISING SURFACE-MODIFIED HYDROXYAPATITE AND USE THEREOF

The present invention relates to a bio-adhesive agent comprising a surface-modified hydroxyapatite and its use. More specifically, the present invention relates to a bio-adhesive agent for the adhesion between bone and bone, bone and tissue, bone and cartilage, or bone and tendon, or for the adhesion of a shield between bones or of an artificial joint, which comprises a surface-modified hydroxyapatite as an active ingredient, wherein the surface-modified hydroxyapatite is characterized in that a certain linker compound is covalently bonded to the surface of the hydroxyapatite; a method for coating the surface of a metal prosthesis using the surface-modified hydroxyapatite; and a metal prosthesis coated with the surface-modified hydroxyapatite obtained by said method. 2. The bio-adhesive agent of claim 1 , wherein the hydroxyapatite is selected from the group consisting of the following i) to x):i) natural and synthesized hydroxyapatite;ii) biological apatite derived from bone or teeth;{'sub': 10', '4', '6', '2, 'sup': 2+', '2+', '2+', '2+', '2+', '2+', '2+', '2+', '2+', '+', '+', '+', '+', '3+', '3+', '3+', '3+', '3+', '4+, 'iii) apatite of the formula M(ZO)Xwherein M is selected from the group consisting of Ca, Cd, Sr, Pb, Zn, Mg, Mn, Fe, Ra, H, HaO, Na, K, Al, Y, Ce, Nd, Laand C;'}{'sub': 10', '4', '6', '2', '4', '3', '4', '4', '4', '4', '4', '4', '4, 'sup': 3−', '3−', '3−', '3−', '3−', '2+', '3−', '4−', '4−, 'iv) apatite of the formula M(ZO)Xwherein Z is selected from the group consisting of PO, CO, CrO, AsO, VO, UO, SO, SiO and GeO;'}{'sub': 10', '4', '6', '2', '3', '3, 'sup': −', '−', '−', '−', '−', '2−', '2−', '2−', '2−, 'v) apatite of the formula M(ZO)Xwherein X is selected from the group consisting of OH, OD, F, Cl, Br, BO, CO, CO and O;'}vi) natural and synthesized hydroxyapatite of the above item i) in the form of a powder, granule, thin film, porous molecule, dense molecule, rod or plate;vii) biological apatite of the above item ii) in the form of a ...

FUNCTIONALIZED ADHESIVE FOR MEDICAL DEVICES

A method for adhering a medical device to biological tissue includes adhering an adhesive composition having a plurality of reactive members of a specific binding pair to tissue which has a plurality of complementary reactive members of the specific binding pair via click chemistry. 1. A method for adhering a medical device to biological tissue comprising:providing a bifunctional adhesive composition having a plurality of reactive members of a first specific binding pair and a plurality of reactive members of a second specific binding pair;providing tissue with a plurality of complementary reactive members of the first specific binding pair;contacting the adhesive composition with the biological tissue, wherein upon contact of the reactive members of the first specific binding pair with the complimentary reactive members of the first specific binding pair associated with the tissue, covalent bonds are formed between the reactive members and the complementary reactive members of the first specific binding pair, thus adhering the adhesive to the tissue;providing a medical device having a plurality of complementary reactive members of the second specific binding pair;contacting the medical device with the adhesive, wherein upon contact of the reactive members of the second specific binding pair with the complimentary reactive members of the second specific binding pair associated with the device, covalent bonds are formed between the reactive members and the complementary reactive members of the second specific binding pair, thus adhering the device to the adhesive composition.2. The method for adhering a medical device to biological tissue according to wherein the members of the first specific binding pair bind to one another via a reaction selected from the group consisting of Huisgen cycloaddition reaction claim 1 , a Diels-Alder reaction and a thiol-ene reaction and the members of the second specific binding pair bind to one another via a reaction selected from the ...

Modified starch material of biocompatible hemostasis

A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

Peg based hydrogel for peripheral nerve injury applications and compositions and method of use of synthetic hydrogel sealants

Hydrogels that may be used for treating peripheral nerves and related methods are provided. Synthetic hydrogel sealants, methods of forming synthetic hydrogel sealants, and the use of synthetic hydrogel sealants are provided.

Thrombin-free biological adhesive and use thereof as a medicament

The invention relates to a thrombin-free, fibrinogen-based biological adhesive for therapeutic use, which comprises factor Vila and a source of calcium ions. The invention also relates to the use of the biological adhesive as a medicament, in particular as a dressing for biological tissues, wounds or biomaterials.

Adhesive complex coacervates and method of making and using thereof

Described herein is the synthesis of adhesive complex coacervates and their use thereof. The adhesive complex coacervates are composed of a mixture of one or more polycations and one or more polyanions. The polycations and polyanions in the adhesive complex coacervate are crosslinked with one another by covalent bonds upon curing. The adhesive complex coacervates have several desirable features when compared to conventional bioadhesives, which are effective in water-based applications. The adhesive complex coacervates described herein exhibit good interfacial tension in water when applied to a substrate (i.e., they spread over the interface rather than being beaded up). Additionally, the ability of the complex coacervate to crosslink intermolecularly increases the cohesive strength of the adhesive complex coacervate. They have numerous biological applications as bioadhesives and drug delivery devices and are particularly useful in underwater applications and situations where water is present such as, for example, physiological conditions.

Light Activated Composite Tissue Adhesives

A light activated collagen-flavin composite layer incorporating riboflavin is applied as treatment for infected lesions caused by bacteria and as the consequence of surgical procedures. These composites have also been found to be strong tissue adhesives that are effective in closing and sealing wounds, fixation of grafts/ implants and anastomoses. Advantages include speed of closure, reduced infection due to the elimination of foreign matter, evidence of accelerated wound healing and the ease of use in complex surgery, especially when watertight seals, limited access or small repair size are important factors. The riboflavin in the collagen layer is exposed to light (e.g., light having a wavelength between 360-375 nm or 440-480 nm), decomposing the riboflavin to form reactive oxygen species (ROS). Strong crosslinks between the collagen composite and tissue results. In addition, similar exposures eradicate pathogens in the wound is eradicated resulting in a sterile wound. In other examples, the composite film may instead contain lumichrome or lumiflavin. 1. A composition , comprising:gelatin, wherein a concentration of the gelatin in the composition is in a range of 20% (w/v) to 50% (w/v);collagen, wherein a concentration of the collagen in the composition is in a range of 10% to 40% (w/v); anda chromophore that produces a reactive oxygen species upon exposure to electromagnetic radiation.2. A composition in accordance with claim 1 , wherein the chromophore includes riboflavin.3. A composition in accordance with claim 1 , wherein a concentration of the riboflavin in the composition is within a range of 0.1% to 2.0% (w/v).4. A composition in accordance with claim 1 , wherein the concentration of the riboflavin in the composition is substantially equal to 1.0%.51. A composition in accordance claim 1 , wherein the chromophore includes lumiflavin.6. A composition in accordance with claim 1 , wherein the chromophore includes lumichrome.7. A composition in accordance with ...

Temporary Embolization Using Inverse Thermosensitive Polymers

One aspect of the present invention relates to methods of embolizing a vascular site in a mammal comprising introducing into the vasculature of a mammal a composition comprising an inverse thermosensitive polymer, wherein said inverse thermosensitive polymer gels in said vasculature, which composition may be injected through a small catheter, and which compositions gel at or below body temperature. In certain embodiments of the methods of embolization, said composition further comprises a marker molecule, such as a dye, radiopaque, or an MRI-visible compound.

Apatite Forming Biomaterial

The present invention relates to chemically bonded ceramic biomaterials, especially a dental material or an implant material. The main binder system forms a chemically bonded ceramic upon hydration thereof, and comprises powdered calcium aluminate and/or calcium silicate, and phase(s) to secure apatite formation at a pH close to neutrality. A second binder system—a cross-linking organic binder system which provides for initial crosslinking of the freshly mixed paste is advantageously added. The invention relates to a powdered composition for preparing the inventive chemically bonded ceramic biomaterial, and a paste from which the biomaterial is formed, as well as a kit comprising the powdered composition and hydration liquid, as well as methods and use of the biomaterial in dental and implant applications with the aim of remineralisation, integration and bone repair.

High Adhesion Antimicrobial Skin Prep Solution and Related Methods

Antimicrobial skin prep solutions of the invention comprise: a major amount of at least one organic solvent, wherein at least about 80% by weight based on total weight of the solvent comprises at least one fugitive organic solvent; an antimicrobially effective amount of at least one antimicrobial agent; and an amount of at least one adhesive effective to increase adhesion of surgical drapes and medical dressings to skin prepped with the antimicrobial skin prep solution, wherein the at least one adhesive is distinct from the at least one antimicrobial agent and is a liquid at room temperature. Coated substrates, applicators, and related methods are also disclosed. 1. An antimicrobial skin prep solution comprising:a major amount of at least one organic solvent, wherein at least about 80% by weight based on total weight of the solvent comprises at least one fugitive organic solvent;an antimicrobially effective amount of at least one antimicrobial agent; andan amount of at least one adhesive effective to increase adhesion of surgical drapes and medical dressings to skin prepped with the antimicrobial skin prep solution,wherein the at least one adhesive is distinct from the at least one antimicrobial agent and is a liquid at room temperature.2. The antimicrobial skin prep solution of claim 1 , wherein the amount of at least one adhesive effective to increase adhesion of surgical drapes and medical dressings to skin prepped with the antimicrobial skin prep solution is about 2% by weight of the skin prep solution.3. The antimicrobial skin prep solution of claim 1 , wherein the amount of at least one adhesive effective to increase adhesion of surgical drapes and medical dressings to skin prepped with the antimicrobial skin prep solution is about 5.5% by weight of the skin prep solution.4. The antimicrobial skin prep solution of claim 1 , wherein the at least one adhesive is a hydrogel in the skin prep solution.5. The antimicrobial skin prep solution of claim 1 , wherein the ...

Bioabsorbable Polymeric Compositions and Medical Devices

The bioabsorbable polymers and compositions of the present invention may be formed into medical devices such as stents that can be crimped onto a catheter system for delivery into a blood vessel. The properties of the bioabsorbable polymers allow for both crimping and expansion of the stent. The crystal properties of the bioabsorbable polymers may change during crimping and/or expansion allowing for improved mechanical properties such as tensile strength and slower degradation kinetics. Typically, bioabsorbable polymers comprise aliphatic polyesters based on lactide backbone such as poly L-lactide, poly D-lactide, poly D,L-lactide, mesolactide, glycolides, lactones, as homopolymers or copolymers, as well as formed in copolymer moieties with co-monomers such as, trimethylene carbonate (TMC) or ε-caprolactone (ECL). 1. A composition comprising a blend formed from poly-L-lactide , poly-D-lactide or mixtures thereof and a copolymer moiety comprising poly-L-lactide or poly-D-lactide linked with β-caprolactone or trimethylcarbonate wherein , the poly-L-lactide or poly-D-lactide sequence in the copolymer moiety is random with respect to the distribution of ε-caprolactone or trimethylcarbonate and where the wide-angle X-ray scattering (WAXS) exhibits 20 values of about 16.48 and about 18.76.2. The composition of wherein the co-polymer moiety comprises poly-L-lactide or poly-D-lactide linked with ε-caprolactone.3. The composition of wherein the polymer moiety comprises poly-L-lactide.4. The composition of wherein the polymer moiety comprises poly-D-lactide.5. The composition of wherein the co-polymer moiety is poly-L-lactide or poly-D-lactide linked with TMC and the molecular weight of the co-polymer ranges from about 1.2 IV to about 2.6 IV.6. The composition of wherein the molecular weight of the co-polymer ranges from about 0.8 to about 6.0.7. The composition of wherein the WAXS 2θ values further comprise peaks at about 11.92 claim 1 , about 20.66 claim 1 , about 22.24 and ...

Medical absorbable hemostatic material for bone wounds and preparation method therefor

A medical absorbable hemostatic and wound healing promoting material for bone wounds and a preparation method thereof. The absorbable hemostatic material for bone wounds is formed of 40-95% of a base material and 5-60% of an adjuvant, based on weight percent, wherein the base material is an oligosaccharide, a polysaccharide, or a mixture of the oligosaccharide and the polysaccharide, and the adjuvant includes (1) one or more polyhydric alcohols, (2) one or more vegetable oils, and (3) one or more emulsifying agents. The method for preparing the absorbable hemostatic and wound healing promoting material for bone wounds comprises mixing a base material and an adjuvant at prescribed amounts by chemical blending or latex blending, cooling to form a solid lump, packaging, and sterilizing.

Methods of building a body portion

An improved method of implanting cells in the body of a patient includes positioning viable cells on a support structure. One or more blood vessels may be connected with the support structure to provide a flow of blood through the support structure. A support structure may be positioned at any desired location in a patient's body. The support structure may be configured to replace an entire organ or a portion of an organ. An organ or portion of an organ may be removed from a body cells and/or other tissue is removed to leave a collagen matrix support structure having a configuration corresponding to the configuration of the organ or portion of an organ. Alternatively, a synthetic support structure may be formed. The synthetic support structure may have a configuration corresponding to a configuration of an entire organ or only a portion of an organ.

BIOLOGIC BONDING AGENT

A sterile biofilm could be engineered to isolate the glue-like substance while eliminating the adverse properties of the bacteria. The resulting sterile glue-like substance would be used to help the cells stick to the support structure. The engineered biofilm could be added to the support structure in the laboratory that produces the support structure or just prior to the addition of the cells by the user. Alternatively, the biofilm and support structure could be combined intra-corporally. This biofilm also could be used as an independent polysaccharide based adhesive with mild to moderate adhesion forces. The biofilm could serve as a surgical adhesion or grouting for cells, for tissue fixation (soft tissue to soft tissue, soft tissue to bone, etc.) and as a sealant. The biofilm could be used in conjunction with other implants and devices. The biofilm could be used to coat a stent. 1. A biologic bonding agent comprising:an engineered adhesive derived at least in part from a bacterial source; andthe adhesive being configured to be collected, processed to be substantially free of viable bacteria, and placed in a container,wherein adhesive properties of the bacterial source are substantially maintained.2. The bonding agent of claim 1 , wherein the bacterial source includes biofilm.3. The bonding agent of claim 1 , wherein at least a portion of the adhesive is polysaccharide based.4. The bonding agent of claim 1 , wherein the adhesive is configured to be coated on or impregnated in at least a portion of an implant.5. The bonding agent of claim 1 , wherein at least a portion of the adhesive is biodegradable.6. The bonding agent of claim 1 , wherein the adhesive is configured to be coated on or impregnated in at least a portion of a stent.7. The bonding agent of claim 1 , wherein the adhesive is configured to be applied to at least a portion of a collagen material.8. The bonding agent of claim 1 , wherein the adhesive is configured to promote attachment of cells to a ...

Pharmaceutical microsphere for embolization

A pharmaceutical microparticle for embolization is disclosed, which includes: a thermoresponsive polymer, an enhancer, a contrast agent, and a solvent. The particle size of pharmaceutical microparticle for embolization is 100-750 μm. The pharmaceutical microparticle for embolization of the present invention is an effective drug carrier, and has biodegradable and X-ray imaging properties. 1. A pharmaceutical microparticle for embolization , comprising:a thermoresponsive polymer;a first enhancer;and a contrast agent;wherein the pharmaceutical microparticle for embolization has a particle size of 100-750 μm.2. The pharmaceutical microparticle for embolization of claim 1 , having a particle size of 200-400 μm.3. The pharmaceutical microparticle for embolization of claim 1 , further comprising a chemical drug.4. The pharmaceutical microparticle for embolization of claim 1 , wherein the chemical drug is a radioactive element compound claim 1 , a fat-soluble drug claim 1 , or a water-soluble drug.5. The pharmaceutical microparticle for embolization of claim 4 , wherein the radioactive element compound is rhenium-188 radioactive element compound claim 4 , yttrium-90 radioactive element compound claim 4 , or holmium-166 radioactive element compound.6. The pharmaceutical microparticle for embolization of claim 5 , wherein the radioactive element compound is rhenium-188-N claim 5 ,N′-1 claim 5 ,2-ethanediylbis-L-cysteine diethylester (ECD) claim 5 , yttrium-90 claim 5 , or holmium-166.7. The pharmaceutical microparticle for embolization of claim 1 , wherein the contrast agent is lipodol or BaSO.8. The pharmaceutical microparticle for embolization of claim 1 , wherein the thermo responsive polymer is present in an amount of 0.3-0.4 parts by weight claim 1 , and the first enhancer is present in an amount of 0.6-0.7 parts by weight.9. The pharmaceutical microparticle for embolization of claim 1 , wherein the thermo responsive material is selected from the group consisting of ...

SILK FIBROIN AND POLYETHYLENE GLYCOL-BASED BIOMATERIALS

This invention relates to methods and compositions for preparation of silk-PEGs based biomaterials through crosslinking by chemically reacting active polyethylene glycols (PEGs) possessing different chemical groups (e.g., thiols and maleimides functionalized PEGs) that are additionally stabilized by the beta-sheet formation of silk fibroin. The crosslinked silk-PEGs biomaterials present strong adhesive properties, which are comparable to or better than the current leading PEG-based sealant, depending on the silk concentration in the silk-PEGs biomaterials. In addition, the silk-PEGs based biomaterials are cytocompatible, show decreased swelling behavior and longer degradation times, which make them suitable for hemostatic applications where the current available tissue sealant products can be contraindicated. 1. A method of preparing a crosslinked polymer matrix , comprising:admixing a composition comprisingat least two functionally activated PEG components capable of reacting with one another to form a crosslinked matrix, andsilk fibroin, wherein beta sheet formation of the silk fibroin further stabilizes the crosslinked matrix.2. The method of claim 1 , wherein the silk fibroin is at a concentration of at least about 10 wt %.3. The method of claim 1 , further comprising exposing the mixture to an alcohol treatment or a water-annealing treatment.4. The method of claim 1 , wherein the silk fibroin is depleted of sericin before admixing with the functionally activated PEG components.5. The method of claim 1 , wherein the crosslinked matrix is a hydrogel claim 1 , a mat claim 1 , a film claim 1 , a sponge claim 1 , a 3-dimensional scaffold claim 1 , a fiber or any combinations thereof.6. The method of claim 1 , wherein each PEG component is a four-armed PEG.7. The method of claim 1 , wherein one of the PEG components is functionally activated with a maleimidyl group.8. The method of claim 7 , wherein one of the PEG components is functionally activated with a thiol ...

MEDICAL ADHESIVE FILM

An adhesive film including an upper surface including a developing reference axis. The adhesive film is simple in structure, accurate in positioning, and convenient for practice. 12. An adhesive film , comprising an upper surface comprising a developing reference axis ().223. The adhesive film of claim 1 , wherein the developing reference axis () is provided with reference numbers ().3. The adhesive film of claim 2 , wherein{'b': 1', '1, 'i': a,', 'b, 'the adhesive film comprises an uppermost adhesive film and a plurality of layers of inner adhesive films (. . . );'}{'b': 1', '1, 'i': a,', 'b, 'the inner adhesive films (. . . ) are disposed beneath the uppermost adhesive film;'}{'b': 2', '2', '2, 'i': a,', 'b, 'each of the inner adhesive films comprises an upper surface comprising a reference axis (. . . ) being the same as the developing reference axis () arranged on the uppermost adhesive film; and'}{'b': 2', '2, 'i': a,', 'b, 'the reference axis (. . . ) arranged on each of the inner adhesive films superposes with one another.'}4221133a,ba,ba,b. The adhesive film of claim 3 , wherein the reference axis (. . . ) arranged on each inner adhesive film (. . . ) is provided with reference numbers (. . . ).52. The adhesive film of claim 1 , wherein the developing reference axis () is in a grid structure formed by arranging transverse lines and vertical lines at equal intervalss between each other.622a,b. The adhesive film of claim 3 , wherein the reference axis (. . . ) arranged on each inner adhesive film is in a grid structure formed by arranging transverse lines and vertical lines at equal intervals between each other.722a,b. The adhesive film of claim 4 , wherein the reference axis (. . . ) arranged on each inner adhesive film is in a grid structure formed by arranging transverse lines and vertical lines at equal intervals between each other.82. The adhesive film of claim 5 , wherein vertical lines and/ or transverse lines of the developing reference axis () ...

SYSTEMS AND METHODS FOR PREPARING AUTOLOGOUS FIBRIN GLUE

The invention provides a system for preparing an autologous solid-fibrin web suitable for regenerating tissue in a living organism. The system includes a sealed primary container containing a separation medium and a low-density high-viscosity liquid. The separation medium is capable of separating red blood cells from plasma when the container contains blood and is centrifuged, and the primary container has a first pressure. The system further includes a sealed secondary container containing a calcium-coagulation activator. The secondary container has a second pressure that is less than the first pressure. The system also includes a transfer device having a cannula with a first end and a second end. The first and second ends are adapted to puncture the sealed primary and secondary containers in order to provide fluid communication between the first and second containers. 1. A system for preparing an autologous solid-fibrin web , the system comprisinga primary container containing plasma and a high-density, low-viscosity fluid;a secondary container configured to receive the plasma from the primary container; anda transfer device capable of providing fluid communication between the primary and secondary containers, and wherein a portion of the plasma moves to the secondary until the high-density, low viscosity fluid from the primary container enters the transfer device.2. The system of claim 1 , wherein the secondary container is evacuated3. The system of claim 2 , wherein the primary container has a first pressure claim 2 , and wherein the secondary container has a second pressure that is less than the first pressure claim 2 , and wherein the plasma in the primary container moves to the secondary container by pressure differentiation.4. The system of claim 1 , wherein the secondary container includes an ionic coagulation activator.5. The system of claim 4 , wherein the ionic coagulation activator is selected from calcium chloride claim 4 , calcium fluoride claim 4 , ...

System for use in bone cement preparation and delivery

A system for use in combining two part preparations, such as bone cement, can include a chamber for intermixing liquid and powder components, a container, a vacuum channel, and a filter. The mixing chamber can be configured to hold a non-liquid, polymer powder component of a bone cement. The container can be configured to hold a liquid component of the bone cement. The vacuum channel can direct a partial vacuum to draw the liquid component from the container into the non-liquid component in the mixing chamber to intermix the components and to thereby provide a settable bone cement.

COMPOSITION CONTAINING INJECTABLE SELF-HARDENED APATITE CEMENT

A method of producing an injectable calcium phosphate paste by a process in which calcium phosphate precursors are mixed with the setting fluids to form a self-hardened apatite cement is disclosed. The produced apatite cement is biocompatible, bioactive and biodegradable in the body. The pH value of said apatite cement is approximately 7 with compressive strength between 10-30 MPa and the setting process will not generate.temperature >37° C. The self-hardened apatite (SHA) cement is found to be bioresorbable and can be used for bone fillers, fixation of broken bones or artificial joints in human and also appropriate for use as a delivery vehicle. 1. A composition of injectable self-hardened apatite cement comprising:{'sub': 3', '4', '2', '4', '4', '2, 'a. a main matrix comprising tri-calcium phosphate (TCP; Ca(PO)) and tetra-calcium phosphate (TTCP; Ca(PO)O),'}{'sub': 2', '3', '6', '8', '7', '6', '5', '3', '7', '2, 'b. hardening agents comprising sodium carbonate (NaCO), citric acid, (CHO) and sodium citrate (CHNaO.2HO),'}c. setting fluids andd. filler and pH stabiliser.2. The composition according to wherein the filler and pH stabiliser is hydroxyapatite (Ca(PO)(OH)).3. The composition according to claim 1 , wherein the weight ratio of tri-calcium phosphate to tetra-calcium phosphate is in the range of 45:55 to 55:45.4. The composition according to claim 1 , wherein said sodium carbonate is present in an amount ranging from about 5 to 10 weight percentage.5. The composition according to claim 1 , wherein said citric acid is present in an amount ranging from about 20 to 30 weight percentage.6. The composition according to claim 1 , wherein said sodium citrate is present in an amount ranging from about 5 to 10 weight percentage.7. The composition according to claim 1 , wherein said filler and/or pH stabiliser is present in an amount ranging from about 1 to 5 weight percentage.8. The composition according to claim 1 , wherein the setting fluids are selected from a ...

STERILIZED LIQUID COMPOSITIONS OF CYANOACRYLATE MONOMER MIXTURES

Cyanoacrylate adhesive compositions comprise a mixture of two cyanoacrylate monomers, including 2-octyl cyanoacrylate and n-butyl cyanoacrylate. The monomers are stabilized and sterilized by irradiation, and do not substantially increase in viscosity after sterilization or after two years of shelf storage. These compositions have anti-microbial properties, and may be used to close wounds as well as secure catheters inserted into the body in place. 1. A cyanoacrylate adhesive composition , comprising a mixture of about 78% to about 82% by weight of monomeric 2-octyl cyanoacrylate , about 22% to about 18% by weight of monomeric n-butyl cyanoacrylate , about 2000 ppm to about 14 ,000 ppm of butylated hydroxyl anisole , and about 10 ppm to about 200 ppm of sulfur dioxide or about 5 ppm to about 50 ppm of an acid stabilizer selected from the group consisting of sulfuric acid , phosphoric acid , and perchloric acid , wherein the composition is sterilized by ethylene oxide or irradiation , the viscosity of the composition increases no more than about 300% after sterilization , the sterilized composition has at least two years of shelf storage stability , and the composition does not contain any plasticizer.2. The cyanoacrylate adhesive composition of claim 1 , wherein the composition comprises a mixture of about 79% to about 81% by weight of monomeric 2-octyl cyanoacrylate claim 1 , about 21% to about 19% by weight of monomeric n-butyl cyanoacrylate claim 1 , about 2000 ppm to about 14 claim 1 ,000 ppm of butylated hydroxyl anisole claim 1 , and about 10 ppm to about 200 ppm of sulfur dioxide.3. The cyanoacrylate adhesive composition of claim 1 , wherein the composition comprises a mixture of about 79% to about 81% by weight of monomeric 2-octyl cyanoacrylate claim 1 , about 21% to about 19% by weight of monomeric n-butyl cyanoacrylate claim 1 , about 2000 ppm to about 8000 ppm of butylated hydroxyl anisole claim 1 , and about 10 ppm to about 200 ppm of sulfur dioxide.4. ...

COMPOSITION I - I AND PRODUCTS AND USES THEREOF

A curable composition apportioned between at least one Part A and at least one Part B, the Parts sealed within barrier means in manner to prevent contamination thereof, the composition comprising: (i) one or more alkenyl-containing prepolymers having at least one alkenyl moiety per molecule, ii) one or more SiH-containing prepolymers having at least one SiH unit per molecule, and additionally: (iii) a catalyst for curing by addition of alkenyl-containing prepolymer (i) to SiH-containing prepolymer (ii), wherein the at least one Part A and at least one Part B are provided within or upon at least two respective receptacles or supports and are adapted to be dispensed or released therefrom in cooperative manner facilitating intimate contact and curing thereof, wherein the receptacle(s) or support(s) for at least one of Part A and Part B is thermally stable at elevated temperature of 123 C for a period in excess of 18 hours, methods for preparing the composition, methods for sterilisation thereof, medical and non-medical use thereof, a device incorporating the composition, and a precursor therefor including its sterilisable precursor composition, in particular a terminally sterilisable or terminally sterile composition for medical use, particularly in wound therapy, more particularly as a wound packing material which can be shaped and configured to the shape of a wound, most particularly for application in negative pressure wound therapy (NPWT). 1. A curable composition , apportioned between at least one Part A and at least one Part B , the composition comprising:one or more alkenyl-containing polymers having at least one, or at least two, alkenyl moiety per molecule,one or more SiH-containing polymers having at least one, or at least two, SiH unit per molecule,a catalyst for curing by addition of an alkenyl-containing polymer to a SiH-containing polymer (ii), anda blowing agent configured to evolve gas as part of or during the curing reaction,wherein the at least one ...

COMPOSITION I-II AND PRODUCTS AND USES THEREOF

A curable composition apportioned between at least one Part A and at least one Part B, the Parts sealed within barrier means preventing contamination, the at least one Part A comprising: (i) one or more alkenyl-group containing prepolymers having at least one alkenyl group or moiety per molecule, and the at least one Part B comprising: (ii) one or more SiH-containing prepolymers having at least one Si—H unit per molecule; the composition additionally comprising: (iii) a catalyst for curing by addition of alkenyl-containing prepolymer (i) to SiH-containing prepolymer (ii), wherein prepolymer (ii) is substantially absent from Part A and prepolymer (i) is substantially absent from Part B, methods for preparing the composition, methods for sterilisation thereof, medical and non-medical use thereof, a device incorporating the composition, and a precursor therefor including its sterilisable precursor composition, in particular a terminally sterilisable or terminally sterile composition for medical use, particularly in wound therapy, more particularly as a wound packing material which can be shaped and configured to the shape of a wound, most particularly for application in negative pressure wound therapy (NPWT). 1. A curable composition apportioned between at least one Part A and at least one Part B , the composition comprising:the at least one Part A comprising one or more alkenyl-group containing polymers having at least one, or at least two, alkenyl group or moiety per molecule,the at least one Part B comprising one or more SiH-containing polymers having at least one, or at least two, Si—H unit or moiety per molecule,a catalyst for curing by addition of an alkenyl-containing polymer to a SiH-containing polymer, anda blowing agent configured to evolve gas as part of or during the curing reaction,wherein the SiH-containing polymer is substantially absent from Part A and the alkenyl-group containing polymer is substantially absent from Part B or Part B incorporates a ...

Lung Volume Reduction Therapy Using Crosslinked Non-Natural Polymers

One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema. 149-. (canceled)50. A method of attaching a first tissue to a second tissue of a patient in need thereof , comprising the step of applying to said first tissue or said second tissue or both an effective amount of a hydrogel , wherein said hydrogel is prepared from(a) a first non-natural polymer and a first cross-linker; said first non-natural polymer comprises a plurality of pendant first nucleophilic groups; and said first cross-linker comprises at least two pendant first electrophilic groups; or(b) a second non-natural polymer and a second cross-linker; said second non-natural polymer comprises a plurality of second electrophilic groups; and said second cross-linker comprises at least two pendant second nucleophilic groups,thereby attaching said first tissue to said second tissue.5155-. (canceled)56. The method of claim 50 , wherein said hydrogel is prepared from a first non-natural polymer and a first cross-linker; and said first nucleophilic groups are selected from the group consisting of alcohols claim 50 , amines ...

TISSUE ADHESIVE BASED ON NITROGEN-MODIFIED ASPARTATES

The invention relates to a polyurea system comprising as component A) isocyanate-functional prepolymers which can be obtained by reacting aliphatic isocyanates A1) with polyols A2) that can have a number-average molecular weight of =400 g/mol and an average OH functionality of 2 to 6 in particular; and as component B) amino-functional aspartic acid esters of the general formula (I) in which X is an organic group containing a secondary amino function, R1, R2 are the same or different organic groups that do not have Zerewitinoff-active hydrogen, and n is a whole number of at least 2, in particular for sealing, bonding, gluing, or covering cell tissue. The invention also relates to a metering system for the polyurea system according to the invention. 115-. (canceled)18. The polyurea system as claimed in claim 17 , wherein Rand Rin each case independently of one another or simultaneously are a linear or branched saturated organic radical optionally also substituted in the chain with heteroatoms.19. The polyurea system as claimed in claim 16 , wherein the radicals Rand Rin each case independently of one another are linear or branched C1 to C10 organic radicals.20. The polyurea system as claimed in claim 17 , wherein Rand Rin each case independently of one another or simultaneously are a linear or branched claim 17 , saturated claim 17 , aliphatic C2 to C6 claim 17 , and the radicals Rand Rin each case independently of one another are linear or branched C2 to C4 aliphatic hydrocarbon radicals.21. The polyurea system as claimed in claim 16 , wherein the polyols A2) contain polyesterpolyols and/or polyester-polyether-polyols and/or polyetherpolyols with an ethylene oxide fraction between 60 and 90% by weight.22. The polyurea system as claimed in claim 16 , wherein the polyols A2) contain polyester-polyether-polyols and/or polyetherpolyols with an ethylene oxide fraction between 60 and 90% by weight.23. The polyurea system as claimed in claim 16 , wherein the polyols A2) ...

Means for Controlled Sealing of Endovascular Devices

Expandable sealing means for endoluminal devices have been developed for controlled activation. The devices have the benefits of a low profile mechanism (for both self-expanding and balloon-expanding prostheses), contained, not open, release of the material, active conformation to the “leak sites” such that leakage areas are filled without disrupting the physical and functional integrity of the prosthesis, and on-demand, controlled activation, that may not be pressure activated.

Bone Cement System For Bone Augmentation

A bone cement is provided that includes a solid component and a liquid component. The solid component and liquid component are mixed together to form the bone cement. After completion of the solid and liquid component mixing, the bone cement has an initial viscosity effective for manual application or manual injection onto or into a targeted anatomical location, e.g., bone, and the cement has stable viscosity range that over both time and temperature is effective for uniformly filling the targeted anatomical location, for example an osteoporotic bone or a fractured vertebral body, with minimal to no leakage of the cement from the targeted anatomical location. Additionally, both the initial viscosity and the stable viscosity of the bone cement are within a range that renders the bone cement effective for injection with a manually operated syringe or multiple syringes. 1. A bone cement formed by a combination of solid and liquid components comprising:a solid component including a contrast agent, a polymerization initiator, a calcium phosphate based bone substitute material, and a solid polymer, anda liquid component including a liquid monomer, a polymerization accelerator, and optionally, a polymerization inhibitor;wherein the bone cement has an initial injectable viscosity suitable for manual injection onto or into a targeted anatomical location, and wherein said initial injectable viscosity being formed substantially immediately after combining the solid component and liquid component.2. The bone cement of claim 1 , wherein the solid component includes:the contrast agent in a range of about 38 to about 42 percent by weight of the solid component;the polymerization initiator in the range of about 0.3 to about 0.5 percent by weight of the solid component;the bone substitute material comprising hydroxyapatite, in the range of about 14 to about 16 percent by weight of the solid component; and,the solid polymer comprising one or more of poly(methylacrylate-co- ...

BIODEGRADABLE PARTICLE, VASCULAR EMBOLIZATION MATERIAL AND METHOD FOR PRODUCING BIODEGRADABLE PARTICLES

A biodegradable particle including a block copolymer produced by copolymerization of a biodegradable copolymer having a structure composed of hydroxycarboxylic acid a1, whose homopolymer produced by homopolymerization has a glass transition point of not less than 40° C. and hydroxycarboxylic acid a2, whose homopolymer produced by homopolymerization has a glass transition point of not more than −40° C.; a water-soluble polymer comprising a functional group selected from the group consisting of a hydroxyl group, amino group and carboxylic acid group at each of both ends; and a polyvalent compound comprising 2 or more functional groups each selected from the group consisting of a hydroxyl group, amino group and carboxylic acid group; wherein a ratio of mass of said structure composed of hydroxycarboxylic acid a2 to mass of said biodegradable copolymer is 30 to 90% by mass. 1. A biodegradable particle comprising a block copolymer produced by copolymerization of:a biodegradable copolymer having a structure composed of hydroxycarboxylic acid a1, whose homopolymer produced by homopolymerization has a glass transition point of not less than 40° C., and hydroxycarboxylic acid a2, whose homopolymer produced by homopolymerization has a glass transition point of not more than −40° C.;a water-soluble polymer comprising a functional group selected from the group consisting of a hydroxyl group, amino group and carboxylic acid group at each of both ends; anda polyvalent compound comprising 2 or more functional groups each selected from the group consisting of a hydroxyl group, amino group and carboxylic acid group;wherein thea ratio of the mass of said structure composed of hydroxycarboxylic acid a2 to the mass of said biodegradable copolymer is 30 to 90% by mass.3. The biodegradable particle according to claim 1 , wherein a 40% compression load in a water-saturated state is not more than 500 mN and claim 1 , when a compression rate in the water-saturated state is 10% claim 1 , ...

PASTE-LIKE BONE CEMENT

Paste containing at least one monomer for radical polymerization, at least one polymer that is soluble in said at least one monomer for radical polymerization, and at least one filling agent that is poorly soluble or insoluble in said at least one monomer for radical polymerization, wherein the filling agent is a particulate inorganic filling agent possessing a BET surface of at least 40 m/g; kit comprising pastes A and B which, when mixed, form paste C, which pastes are useful for mechanical fixation of articular endoprostheses, for covering skull defects, for filling bone cavities, for femuroplasty, for vertebroplasty, for kyphoplasty, for the manufacture of spacers or for the production of carrier materials for local antibiotics therapy, as well as a form body produced from the pastes. 1. Paste containing at least one monomer for radical polymerization , at least one polymer that is soluble in said at least one monomer for radical polymerization , and at least one filling agent that is poorly soluble or insoluble in said at least one monomer for radical polymerization , wherein the filling agent is a particulate inorganic filling agent possessing a BET surface of at least 40 m/g.2. Paste according to claim 1 , whereby the particulate inorganic filling agent comprises hydroxy groups that are bound covalently to the particles.3. Paste according to claim 2 , wherein the particulate inorganic filling agent comprises Ho—Si groups (silanol groups) that are bound covalently to the particles.4. Paste according to claim 1 , wherein the particulate inorganic filling agent is selected from the group consisting of pyrogenic silicon dioxide claim 1 , pyrogenic silicon dioxide made hydrophobic claim 1 , pyrogenic metal-silicon mixed oxides claim 1 , titanium dioxide claim 1 , bentonite claim 1 , montmorillonite claim 1 , and a mixture of at least two of these substances.5. Paste according to claim 4 , wherein the particulate inorganic filling agent is pyrogenic silicon dioxide ...

Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels

Pharmaceutically acceptable hydrogel polymers of natural, recombinant or synthetic origin, or hybrids thereof, are introduced in a dry, less hydrated, or substantially deswollen state and rehydrate in a physiological environment to undergo a volumetric expansion and to affect sealing, plugging, or augmentation of tissue, defects in tissue, or of organs. The hydrogel polymers may deliver therapeutic entities by controlled release at the site. Methods to form useful devices from such polymers, and to implant the devices are provided.

TISSUE ADHESIVE WITH ACCELERATED CURING

The present invention relates to a polyurea system encompassing as component A) isocyanate-functional prepolymers obtainable by reaction of aliphatic isocyanates A1) with polyols A2), which can in particular have a number average molecular weight of ≧400 g/mol and an average OH functionality of 2 to 6, as component B) amino-functional compounds of general formula (I) in which X is an organic residue comprising a tertiary amino function, having no Zerewitinoff active hydrogen, Ris a CH—COORresidue, in which Ris an organic residue having no Zerewitinoff active hydrogen, a linear or branched C1 to C4 alkyl residue, a cyclopentyl or cyclohexyl residue or H, Ris an organic residue having no Zerewitinoff active hydrogen, n is an integer ≧2 or ≦3, in particular for closing, binding, bonding or covering cell tissue, and to a metering system for the polyurea system according to the invention. 114-. (canceled)17. The polyurea system according to claim 16 , wherein R claim 16 , R claim 16 , Rare claim 16 , each independently of one another or simultaneously claim 16 , a linear or branched claim 16 , saturated organic residue that is optionally also substituted in the chain with heteroatoms claim 16 , in particular a linear or branched claim 16 , saturated claim 16 , aliphatic C1 to C10 claim 16 , preferably C2 to C8 and particularly preferably C2 to C6 hydrocarbon residue.18. The polyurea system according to claim 17 , wherein R claim 17 , R claim 17 , Rare claim 17 , each independently of one another or simultaneously claim 17 , a methyl claim 17 , ethyl claim 17 , propyl or butyl residue claim 17 , wherein at least one of R claim 17 , R claim 17 , Ris a methylene claim 17 , ethylene claim 17 , propylene or butylene residue.19. The polyurea system according to wherein R claim 15 , Rand optionally Rare claim 15 , each independently of one another or simultaneously claim 15 , a linear or branched C1 to C10 claim 15 , preferably C1 to C8 claim 15 , particularly preferably C2 to ...

Adhesive composition for soft tissues, adhesive composition for wound dressing or wound dressing composition

The present invention provides an adhesive composition for soft tissues, an adhesive composition for wound dressing or a wound dressing composition, not only having low toxicity, low harmfulness and high adhesive strength but also being excellent in workability during application and being capable of forming films of excellent properties. The compound of the present invention is comprised a monomer (A), polymer particles (B) having a specific weight-average molecular weight and a specific volume mean particle diameter, and a polymerization initiator composition (C) containing an organoboron compound is produced.

BIORESORBABLE EMBOLIZATION MICROSPHERES

The present disclosure is generally directed to an embolic material which, in some embodiments, may be in the form of a microsphere or a plurality of microspheres. The embolic material generally comprises carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). In some embodiments, the embolic material may further comprise a therapeutic agent, such as doxorubicin. 1. An embolic material comprising at least one microsphere comprising carboxymethyl chitosan crosslinked with carboxymethyl cellulose.2. The embolic material of claim 1 , wherein the microsphere comprises a diameter between about 100 micrometers and about 1200 micrometers.3. The embolic material of claim 1 , wherein the microsphere comprises a diameter of between about 300 micrometers and about 500 micrometers.4. The embolic material of claim 1 , wherein the microsphere comprises a diameter of between about 100 micrometers and about 300 micrometers.5. The embolic material of claim 1 , wherein the microsphere comprises a diameter of between about 700 micrometers and about 900 micrometers.6. The embolic material of claim 1 , wherein the microsphere comprises a diameter of between about 900 micrometers and about 1200 micrometers.7. The embolic material of claim 1 , wherein the microsphere further comprises a therapeutic agent.8. The embolic material of claim 7 , wherein the therapeutic agent comprises a chemotherapeutic agent.9. The embolic material of claim 7 , wherein the therapeutic agent comprises at least one positively charged functional group.10. The embolic material of claim 7 , wherein the therapeutic agent comprises at least one of irinotecan claim 7 , ambroxol claim 7 , or doxorubicin.11. The embolic material of claim 7 , wherein a concentration of the therapeutic agent is between about 0.3 milligram of therapeutic agent per milligram of dry microsphere and about 0.75 milligram of therapeutic agent per milligram of dry microsphere.12. The embolic material of claim 1 , wherein ...

Bone Cement With Adapted Mechanical Properties

A bone cement is shown that includes a monomer, and a non-reactive substance that is fully miscible with the monomer. A resulting cured bone cement exhibits desirable properties such as modification in a stiffness of the material. Modified properties such a stiffness can be tailored to match bone properties and reduce an occurrence of fractures adjacent to a region repaired with bone cement. One example includes adjacent vertebral body fractures in vertebroplasty procedures. 1. A method of forming bone cement , comprising:identifying a mechanical property of bone;forming a fluid phase, comprising mixing a monomer and a polymerizing agent;adding a powder phase to the fluid phase; andadding a miscible substance to the fluid phase in an amount sufficient to substantially match a mechanical property of the bone cement to the identified mechanical property of bone.2. The method of claim 1 , wherein the substance comprises an amount between 20% and 60% of the fluid phase.3. The method of claim 1 , wherein the substance comprises an amount between 30% and 60% of the fluid phase.4. The method of claim 1 , wherein the substance comprises an amount between 30% and 50% of the fluid phase.5. The method of claim 1 , wherein the substance comprises an amount between 20% and 45% of the fluid phase.6. The method of claim 1 , wherein the substance comprises an amount of between 20% and 30% of the fluid phase.7. The method of claim 1 , wherein the substance comprises an amount of about 25% of a total liquid component.8. The method of claim 1 , further including adding a radiopaque agent to the fluid phase.9. The method of claim 1 , wherein the powder phase comprises poly methyl methacrylate (PMMA) powder.10. The method of claim 1 , wherein the powder phase comprises hydroxyapatite powder.11. The method of claim 1 , wherein the miscible substance does not react with the powder phase.12. The method of claim 1 , wherein the substance creates a microporous structure in the bone cement.13 ...

Bioadhesive for Soft Tissue Repair

The present invention provides compositions and methods for repair and reconstruction of defects and injuries to soft tissues. Some aspects of the invention provide tissue adhesives comprising a hybrid hydrogel by using a naturally derived polymer, gelatin and a synthetic polymer, polyethylene glycol, wherein the hydrogel is biocompatible, biodegradable, transparent, strongly adhesive to corneal tissue, and have a smooth surface and biomechanical properties similar to the cornea.

Composition for hemostasis and container comprising same

The present invention relates to a composition for hemostasis which contains collagen, stabilizer, and thrombin, and a container including the same. The present invention is applicable to a bleeding patient requiring emergency treatment with a simple method of use. There is no toxicity and no problem of blood infection. A biodegradation rate is fast. In this regard, the present invention achieves an excellent hemostatic effect. Therefore, the composition for hemostasis is useful as a hemostat. 1. A composition for hemostasis comprising collagen;stabilizer; andthrombin,wherein the stabilizer is disposed between the collagen and the thrombin so that the collagen and the thrombin are separated from each other.2. The composition of claim 1 , wherein the collagen is crosslinked collagen.3. The composition of claim 2 , wherein the crosslinked collagen is prepared using a preparing method including(S1) a step of treating the collagen with ethanol or methanol,(S2) a step of preparing collagen solution having pH 2 to pH 4 by adding acid to the collagen treated in the step (S1),(S3) a step of preparing esterified collagen by performing centrifugation on the collagen solution prepared in the step (S2) after bringing the collagen solution into a neutral state,(S4) a step of preparing the crosslinked collagen by adding a crosslinking agent to esterified collagen prepared in the step of (S3), and(S5) a step of performing freeze drying on the crosslinked collagen prepared in the step (S4) after the crosslinked collagen is dispersed into purified water.4. The composition of claim 2 , wherein a molecular weight of the crosslinked collagen is 100 claim 2 ,000 to 1 claim 2 ,000 claim 2 ,000 Dalton.5. The composition of claim 1 , wherein the collagen is included as much as 40 to 97 weight % in a gross weight of the composition for hemostasis.6. The composition of claim 1 , wherein the stabilizer is at least one selected from a group consisting of albumin (human serum albumin) claim 1 , ...

ONE COMPONENT FIBRIN GLUE COMPRISING A POLYMERIZATION INHIBITOR

Provided herein are stable liquid sealant formulations comprising fibrin monomers and a reversible fibrin polymerization blocking agent, methods of preparing and using the formulations. 113-. (canceled)14. A method for preparing a sealant at a surface comprising: providing a liquid sealant formulation comprising fibrin monomers at a concentration of 1 to 13% (w/v) and a GPRP peptide for reversible blocking fibrin polymerization wherein the GPRP peptide is present in the formulation in an amount which is greater than 100-fold molar excess relative to the fibrin monomers; and wherein the liquid formulation is stable for at least 14 days at an ambient temperature selected from the group consisting of about 20 , 21 , 22 , 23 , 24 , and 25° C.; and applying the formulation to the surface under conditions which facilitate fibrin polymerization at the surface.15. The method of claim 14 , wherein the conditions comprise removing claim 14 , blocking claim 14 , neutralizing and/or diluting the GPRP peptide.1620-. (canceled)21. A method of healing claim 14 , sealing and/or reducing blood loss in a subject in need claim 14 , comprising applying to the subject an effective amount of a liquid sealant formulation comprising fibrin monomers at a concentration of 1 to 13% (w/v) and a GPRP peptide for reversible blocking fibrin polymerization wherein the GPRP peptide is present in the formulation in an amount which is greater than 100-fold molar excess relative to the fibrin monomers; and wherein the liquid formulation is stable for at least 14 days at an ambient temperature selected from the group consisting of about 20 claim 14 , 21 claim 14 , 22 claim 14 , 23 claim 14 , 24 claim 14 , and 25° C.22. (canceled) The instant application contains a Sequence Listing, which is submitted concomitantly with this application via EFS-Web in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Dec. 22, 2013, is named “sequencelisting” and is 8 ...

HYDROGELS AND USE THEREOF IN ANASTOMOSIS PROCEDURES

This disclosure provides novel hydrogels that can undergo multiple gel-sol transitions and methods of making and using such hydrogels, particularly in anastomosis procedures. The peptide hydrogels comprising a fibrillar network of peptides that are in an amphiphilic β-hairpin conformation. The peptides comprise photo-caged glutamate residues with a neutral photocage that can be photolytically selectively uncaged to disrupt the fibrillar network and trigger an irreversible gel-sol phase transition of the hydrogel. Isolated peptides for making the disclosed hydrogels are provided, as are methods of using the peptide hydrogels in anastomosis procedures. 1. A peptide hydrogel comprising a fibrillar network of peptides , wherein:the hydrogel undergoes a gel-sol phase transition upon application of shear stress, and a sol-gel phase transition upon removal of the shear stress; andthe peptides are in an amphiphilic β-hairpin conformation and comprise photo-caged glutamate residues with a neutral photocage that can be photolytically selectively uncaged to disrupt the fibrillar network and trigger an irreversible gel-sol phase transition of the hydrogel.2. The peptide hydrogel of claim 1 , wherein:the amphiphilic β-hairpin conformation comprises a β-turn, a first β-strand, a second β-strand, a hydrophobic face, and a hydrophilic face;the assembly of the peptides in the fibrillar network comprises hydrophobic interactions between the hydrophobic faces of the peptides;the first β-strand comprises the photocaged glutamate residue, the second β-strand comprises a glycine residue, and the sidechains of the photocaged glutamate residue and the glycine residue are proximal to each other on the hydrophobic faces of the peptides; anduncaging the photocaged glutamate residues disrupts the hydrophobic interactions between the peptides by exposing negative charges of the glutamate residues, thereby disrupting the fibrillar network and triggering the irreversible gel-sol phase transition ...

EMULSIONS OR MICROEMULSIONS FOR USE IN ENDOSCOPIC MUCOSAL RESECTIONING AND/OR ENDOSCOPIC SUBMUCOSAL DISSECTION

The present invention relates to a pharmaceutical composition in form of emulsion or microemulsion and the use thereof as aid during endoscopic procedures in which it is injected in a target tissue in order to form a cushion. More in details, the invention relates to a method for performing an endoscopic procedure, which comprises injecting said pharmaceutical composition in form of emulsion or microemulsion in a target tissue of a patient, in order to form a cushion, which cushion is then optionally subjected to an endoscopic surgical procedure, such as a resection. 1. A kit comprising a pharmaceutical composition in a container , wherein the pharmaceutical composition comprises:(a) at least one poloxamer selected from poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338, and poloxamer 407, or a mixture thereof; and(b) means for keeping the pharmaceutical composition in liquid phase up to a temperature of about 40° C. in vitro.2. The kit according to claim 1 , wherein the container is selected from an ampoule claim 1 , a vial claim 1 , a bottle claim 1 , and a pre-filled syringe.3. The kit according to claim 2 , wherein the container is an ampoule.4. The kit according to claim 3 , wherein the ampoule contains from 10 mL to 50 mL of the pharmaceutical composition.5. The kit according to claim 2 , wherein the container is a vial.6. The kit according to claim 5 , wherein the vial contains from 10 mL to 50 mL of the pharmaceutical composition.7. The kit according to claim 2 , wherein the container is a bottle.8. The kit according to claim 2 , wherein the container is a pre-filled syringe.9. The kit according to claim 8 , wherein the pre-filled syringe contains from 5 mL to 10 mL of the pharmaceutical composition.10. A method for creating a cushion in a submucosal tissue in the gastrointestinal tract of a patient claim 8 , comprising injecting into the submucosal tissue a pharmaceutical composition comprising:(a) at least one poloxamer selected from poloxamer 124, ...

A MEDICAL IMPLANT AND A METHOD OF COATING A MEDICAL IMPLANT

A synthetic bead is for implantation within the body of an animal or human body. The bead includes a surface defining a shape having a bulk volume of the bead. The surface of the bead is coated with at least a first therapeutic agent to form an inner layer; and an outer layer includes a biodegradable polymer and a second therapeutic agent positioned above the inner layer. 1. A medical implant comprising an implant surface , the surface comprising:an inner layer comprising a first bioceramic material and a first therapeutic agent; andan outer layer comprising a biodegradable polymer and a second therapeutic agent.2. A medical implant in accordance with wherein the outer layer further comprises a second bioceramic material.3. A medical implant in accordance with wherein the second bioceramic material is dispersed throughout the matrix of the biodegradable polymer.4. A medical implant in accordance with any one of the preceding claims wherein the biodegradable polymer is selected from the group comprising: Poly lactic acid (PLA) claim 2 , poly glycolic acid (PGA) claim 2 , Poly lactic co-glycolic acid (PLGA) claim 2 , and copolymers with polyethylene glycol (PEG); polyanhydrides claim 2 , poly(ortho)esters claim 2 , polyurethanes claim 2 , poly(butyric acid) claim 2 , poly(valeric acid) claim 2 , poly(lactide-co-caprolactone) and trimethylene carbonate and combinations and co-polymers thereof.5. A medical implant in accordance with any one of the preceding claims wherein the bioceramic material is selected from the group comprising of hydroxyapatite claim 2 , tricalcium phosphate claim 2 , bioglass claim 2 , calcium phosphate or bone or a combination thereof.6. A medical implant in accordance with any one of the preceding claims wherein the bioceramic material is hydroxyapatite and wherein the hydroxyapatite comprises one or more of the following ions selected from the group consisting of calcium claim 2 , phosphates claim 2 , fluorine claim 2 , strontium claim 2 , ...

Self-Assembling Biomimetic Hydrogels Having Bioadhesive Properties

The disclosure relates to a composition that is liquid at a temperature below the body temperature of a mammal and that solidifies at or above the body temperature of the mammal. The composition includes a thermally-desolubilizable polymer interspersed with a polymeric component of extracellular matrix and an encapsulated form of an amine compound (preferably an aminated component of extracellular matrix) that is de-encapsulated in the body of the mammal. The polymeric component is able to form covalent bonds with amine moieties in the aminated component, in one or more tissues in the body of the mammal, or both. Upon injection off liquid suspension of these components into the body of the mammal, the thermally-desolubilizable polymer condenses, entrapping the polymeric component. The polymeric component binds covalently with a tissue in the body, and the aminated component end-caps the remaining reactive moieties of the polymeric component, forming a matrix at the site of injection. The disclosure also relates to uses of such compositions for forming a matrix on or within the body of a mammal. The compositions have a variety of uses, such as bioadhesives, as sealants for ruptured tissues, as drug or imaging agent depots, or as mechanical cushions. 1101-. (canceled)102. A method of forming a solidified matrix fixed within the body of a mammal , the method comprising: a) a biocompatible thermally-desolubilizable (TD) polymer selected from the group consisting of poly(ethylene oxides) (PEOs), poly(propylene oxides) (PPOs), copolymers of PEO and poly(lactide acid) (PLA), poly (n-isopropyl acrylamides) (PNIPPAms), mixtures and copolymers thereof, wherein the polymer exists in an extended form below a critical solution temperature (CST) that is lower than the normal body temperature of the mammal and in a condensed form at or above the CST;', 'b) an aminated component of a mammalian extracellular matrix, in a releasable encapsulated form, wherein the aminated component ...

A conductive elastomer, preparation method and use thereof

A preparation method of a conductive elastomer includes the following steps: (1) according to the mass percent of 20˜75%, dissolving the metallic salts into deionized water to form an electrolyte solution, wherein said metallic salts is either of magnesium nitrate, sodium nitrate, zinc nitrate, cesium nitrate, calcium nitrate, neodymium nitrate, aluminum nitrate, potassium nitrate, potassium chloride, magnesium chloride, calcium chloride, sodium chloride, zinc chloride, cesium chloride, aluminum chloride or their combinations; (2) according to the mass percent of 10˜40%, mixing starches into the electrolyte solution prepared in step (1), then at the temperature of 33˜120 ° C., stirring to gelatinize the starches, forming a viscous liquid; (3) standing the viscous liquid obtained in step (2) at 25˜90° C. for 10 min to 48 h to obtain the conductive elastomer.

Electrically conductive adhesive

One aspect refers to an electrically conductive adhesive including a) a (meth)acrylate monomer, b) a polymer being soluble in the (meth)acrylate monomer, c) a biocompatible metal having a median particle size d50 of below 50 μm, and d) a polymerization initiator. One aspect also refers to a kit for preparing an electrically conductive adhesive, to an implantable medical device including such an electrically conductive adhesive, or a cured form thereof, and to the use of such an electrically conductive adhesive.

Injectable, Biodegradable Bone Cements and Methods of Making and Using Same

Compositions of, methods of making, and methods of using alkaline earth phosphate bone cements are disclosed. A bone cement composition includes a powder comprising a basic source of calcium, magnesium, or strontium, a setting solution comprising H3PO4 and a buffer, and a biocompatible polymer that is incorporated into the setting solution. The powder is mixed with the setting solution to form a bone cement paste that either (a) sets into a hardened mass, or (b) is irradiated with electromagnetic radiation to form dry powders, the dry powders then being mixed with a second setting solution to form a radiation-assisted bone cement paste that sets into a hardened mass. 1. A bone cement composition comprising:a powder comprising a basic source of calcium, magnesium, or strontium;{'sub': 3', '4, 'a setting solution comprising HPOand a buffer; and'}a biocompatible polymer that is incorporated into the setting solution;wherein the powder is mixed with the setting solution to form a bone cement paste that either (a) sets into a hardened mass, or (b) is irradiated with electromagnetic radiation to form dry powders, the dry powders then being mixed with a second setting solution to form a radiation-assisted bone cement paste that sets into a hardened mass.2. The bone cement of wherein the powder comprises Ca(OH) claim 1 , Mg(OH) claim 1 , or Sr(OH).3. (canceled)4. The bone cement of wherein the biocompatible polymer comprises chitosan.5. The bone cement of wherein the biocompatible polymer is surface-phosphorylated prior to being incorporated into the setting solution.6. The bone cement of wherein the setting solution further comprises citric acid monohydrate.79-. (canceled)10. The bone cement composition of further comprising an additive selected from the group consisting of: proteins claim 1 , osteoinductive materials claim 1 , osteoconductive materials claim 1 , X-ray opacifying agents claim 1 , medicaments claim 1 , supporting or strengthening filler materials claim 1 , ...

TWO-REACTANT SHEET-SHAPED ADHESIVE/REINFORCEMENT FOR TISSUES

A sheet-shaped tissue adhesive/reinforcement includes a base sheet having biodegradability and a communicative porous structure, and an adhesive resin layer fixed and formed on the base sheet. The adhesive resin layer includes a first reactant made of an aldehyded glycan and a second reactant made of partially carboxylated polylysine, and has a molar ratio of 1 as a ratio of an aldehyde group of the first reactant to an amine group of the second reactant. The adhesive resin layer has a structure of granules derived from powder of the first reactant, and a connecting layer derived from the second reactant. The connecting layer connects the granules to each other and fixes each of the granules onto the base sheet, throughout the sheet-shaped tissue adhesive/reinforcement. 1. A sheet-shaped tissue adhesive/reinforcement comprising:a base sheet having biodegradability and a communicative porous structure; andan adhesive resin layer fixed and formed on the base sheet,the adhesive resin layer includinga first reactant made of aldehyded glycan, anda second reactant made of partially carboxylated polylysine, and the adhesive resin layer havinga molar ratio of 1 as a ratio of an aldehyde group of the first reactant to an amine group of the second reactant,a structure of granules derived from powder of the first reactant, anda connecting layer derived from the second reactant, the connecting layer connecting the granules with each other and fixing each of the granules onto the base sheet, throughout the sheet-shaped tissue adhesive/reinforcement.2. The sheet-shaped tissue adhesive/reinforcement according to claim 1 , whereinthe base sheet is non-woven fabric, woven fabric, knitted fabric, mesh sheet, sponge sheet, or other continuous porous sheet, and has a thickness of 15 μm to 500 μm, andthe adhesive resin layer has a thickness of 100 μm to 800 μm.3. The sheet-shaped tissue adhesive/reinforcement according to claim 1 , wherein the granules derived from the powder of the ...

IMPLANTATION DEVICES INCLUDING HYDROGEL FILAMENTS

Described are devices for implantation comprising a hydrogel filament wherein the hydrogel filament includes a low molecular weight ethylenically unsaturated macromer, an ethylenically unsaturated monomer, and a visualization agent. Methods of making and using these devices are also described. 1. A device for implantation comprising:a hydrogel filament attached to a coupler wherein the coupler is attached to a pusher,wherein the hydrogel filament includes a low molecular weight ethylenically unsaturated macromer; an ethylenically unsaturated monomer; and a visualization agent,wherein said device contains no support members.2. The device of claim 1 , wherein said macromer has a molecular weight of about 100 grams/mole to about 5000 grams/mole.3. The device of claim 1 , wherein said macromer comprises polyethylene glycol claim 1 , propylene glycol claim 1 , poly(tetramethylene oxide) claim 1 , poly(ethylene glycol) diacrylamide claim 1 , poly(ethylene glycol) diacrylate claim 1 , poly(ethylene glycol) dimethacrylate claim 1 , derivatives thereof claim 1 , or combinations thereof.4. The device of claim 1 , wherein said visualization agent comprises an aromatic ring having a single unsaturation point and at least one iodine atom.5. The device of claim 1 , wherein said visualization agent comprises barium sulfate claim 1 , gadolinium claim 1 , or iron oxide.6. The device of claim 5 , wherein said visualization agent is barium sulfate.7. The device of claim 1 , wherein said ethylenically unsaturated monomer and said visualization agent comprise 2 claim 1 ,4 claim 1 ,6-triiodophenyl penta-4-enoate claim 1 , 5-acrylamido-2 claim 1 ,4 claim 1 ,6-triiodo-n claim 1 ,n′-bis-(2 claim 1 ,3 dihydroxypropyl) isophthalamide claim 1 , derivatives thereof claim 1 , or combinations thereof.8. The device of claim 1 , wherein said macromer and said monomer are crosslinked with N claim 1 ,N claim 1 ,N′ claim 1 ,N′-tetramethylethylenediamine claim 1 , ammonium persulfate claim 1 , ...

Adhesive Composition

The present invention relates to an adhesive composition applicable to skin comprising: (i) a polar oil or fat including (a) at least one triglyceride and/or (b) at least one fatty acid of the formula R—COH, wherein R is a Cto Calkyl group; and (ii) at least one homopolymer, and/or copolymer. This invention also relates to a medical adhesive device including such adhesive composition. 2. (canceled)3. (canceled)4. (canceled)5. The adhesive composition of further comprising at least one tackifier.6. The adhesive composition of claim 5 , wherein the tackifier is selected from the group consisting of natural rosin claim 5 , modified rosin claim 5 , glycerol ester of natural rosin claim 5 , glycerol ester of modified rosin claim 5 , pentaerythritol ester of natural rosin claim 5 , pentaerythritol ester of modified rosin claim 5 , phenolic-modified terpene resin claim 5 , aliphatic petroleum hydrocarbon resin claim 5 , and cycloaliphatic resin.7. (canceled)8. (canceled)9. The adhesive composition of claim 1 , wherein the base polymer comprises at least two immiscible monomers.10. The adhesive composition of further comprising a hydrophilic fluid-absorbing gum or gel-thickener claim 1 , wherein the gum or gel-thickener is cationic claim 1 , anionic claim 1 , or non-ionic.11. The adhesive composition of claim 10 , wherein the gel-thickener is a water soluble or swellable hydrocolloid or a mixture thereof.12. The adhesive composition of claim 11 , wherein the gel-thickener is selected from a group consisting of carboxymethylcellulose claim 11 , hydroxyethylcellulose (HEC) claim 11 , hydroxypropylcellulose (HPC) claim 11 , pectin claim 11 , carrageenan claim 11 , and gelatin.13. A medical adhesive device comprising an adhesive composition comprising coconut oil claim 11 , a mineral oil claim 11 , and a base polymer.14. The adhesive device of claim 13 , wherein the adhesive composition further comprises a tackifier.15. The adhesive device of claim 14 , wherein the tackifier is ...

OSTOMY DEVICE

Disclosed is an ostomy device with an adhesive wafer for attachment to a skin surface of a user and a collecting bag for collecting output from a stoma. The collecting bag is connected to the adhesive wafer, and the adhesive wafer has a through-going hole for accommodating the stoma of the user. The adhesive wafer includes a backing layer, a first switchable adhesive composition (), a second absorbent adhesive composition (), and a release liner. 125-. (canceled)26. An ostomy device comprising an adhesive wafer for attachment to a skin surface of a user , and a collecting bag connected to the adhesive wafer; the adhesive wafer having a through-going hole for accommodating the stoma of the user; and the adhesive wafer comprising a backing layer , a first switchable adhesive composition , a second absorbent adhesive composition , and a release liner , wherein the adhesive wafer has a central part adjacent to the hole for accommodating the stoma and a peripheral part adjacent to an edge of the adhesive wafer away from the hole , and wherein the second absorbent adhesive composition is located at least in the central part of the adhesive wafer , wherein the release liner is in contact with the first switchable adhesive composition in the peripheral part of the adhesive wafer , and wherein the release liner is in contact with the second absorbent adhesive composition in the central part of the adhesive wafer.27. The ostomy device according to claim 26 , wherein the switchable adhesive composition is switchable from a high-tack state with a first peel force to a lower-tack state with a second peel force.28. The ostomy device according to claim 27 , wherein the first peel force is higher than the second peel force.29. The ostomy device according to claim 27 , wherein the peel force is measured by a 90 degree peel test.30. The ostomy device according to claim 27 , wherein a reduction in peel force between the first peel force and the second peel force is at least 50%.31. ...

METHOD AND APPARATUS FOR DERMATOLOGICAL TREATMENT

Exemplary methods and systems can be provided for resurfacing of skin that include formation of a plurality of small holes, e.g., having widths greater than about 0.2 mm and less than about 0.7 mm or 0.5 mm, using a mechanical apparatus. Compressive and/or tensile forces can then be applied to the treated region of skin as the damage heals to facilitate hole closure, and provide enhanced and/or directional shrinkage of the treated skin area. 1. A cosmetic method for producing an effect in skin , tissue , comprising:forming a plurality of holes in a region of the skin tissue using at least one coring needle; andproviding a stress that is at least one of a compressive stress or a tensile stress in the region of skin tissue after forming the holes,wherein a diameter of the holes is between 0.2 mm and 0.7 mm,wherein the holes extend from the skin surface into the dermal layer of the skin, wherein the holes extend over an areal fraction of a surface of the region that is between 5% and 50%,wherein the stress provides a force in the region, along a direction that is parallel, to the surface of the region, andwherein the stress is maintained on the surface of the region until the holes have closed.2. The method of claim 1 , wherein a diameter of the holes is between 0.2 mm and 0.5 mm.3. The method of claim 1 , wherein the holes ex tend over the areal fraction of the surface of the region that is between 10% and 30%.4. The method of claim 1 , wherein the holes extend through an. entire depth of the dermal layer.5. The method of claim 1 , wherein the stress is the compressive stress which is provided by adhering a pre-stretched film over at least one portion of the region claim 1 ,6. The method of claim 5 , further comprising adhering a rigid object onto the pre-stretched. film after the pre-stretched film has been adhered to the at least one portion of the region.7. The method of claim 6 , wherein the rigid object is at least one of a rigid film or a plate.8. The method of ...

Temporary Embolization Using Inverse Thermosensitive Polymers

One aspect of the present invention relates to methods of embolizing a vascular site in a mammal comprising introducing into the vasculature of a mammal a composition comprising an inverse thermosensitive polymer, wherein said inverse thermosensitive polymer gels in said vasculature, which composition may be injected through a small catheter, and which compositions gel at or below body temperature. In certain embodiments of the methods of embolization, said composition further comprises a marker molecule, such as a dye, radiopaque, or an MRI-visible compound. 1. A method of temporarily embolizing a vascular site in a mammal , comprising the step of:introducing into the vasculature of a mammal a composition comprising an inverse thermosensitive polymer, wherein said inverse thermosensitive polymer gels in said vasculature, thereby temporarily embolizing a vascular site of said mammal.2. The method of claim 1 , wherein said mammal is a human.3. The method of claim 1 , wherein the transition temperature of said inverse thermosensitive polymer is between about 10 C and about 40 C.4. The method of claim 1 , wherein the volume of the inverse thermosensitive polymer between its transition temperature and physiological temperature is between about 80% and about 150% of the volume of the inverse thermosensitive polymer below its transition temperature.5. The method of claim 1 , wherein said inverse thermosensitive polymer is a block copolymer claim 1 , random copolymer claim 1 , graft polymer claim 1 , or branched copolymer.6. The method of claim 1 , wherein said inverse thermosensitive polymer is a block copolymer.7. The method of claim 1 , wherein said inverse thermosensitive polymer is a polyoxyalkylene block copolymer.8. The method of claim 1 , wherein said inverse thermosensitive polymer is a poloxamer or poloxamine.9. The method of claim 1 , wherein said inverse thermosensitive polymer is a poloxamer.10. The method of claim 1 , wherein said inverse thermosensitive ...

ANTI-ADHESION POLYMER COMPOSITION CAPABLE OF SUPPORTING GROWTH FACTOR

The present invention relates to an anti-adhesion polymer composition capable of supporting growth factor, which effectively exhibits anti-adhesion function and, at the same time, has an excellent adhesive property so as to be able to easily and continuously adhere to a wound site, has antibacterial and hemostatic properties, and is composed of an injectable formulation suitable for use in minimally invasive surgery, laparoscopic surgery or the like. The anti-adhesion polymer composition capable of supporting growth factor comprises: 24-50 wt % of a polyethyleneglycol-polypropyleneglycol-polyethyleneglycol (PEG-PPG-PEG) block copolymer having a polyethyleneglycol (PEG) content of 65-85 wt % and a molecular weight of 6,000-20,000 Da; 0.03-5 wt % of gelatin; 0.03-5 wt % of chitosan; and distilled water. 1. An anti-adhesion polymer composition capable of supporting growth factor , the composition comprising: 24-50 wt % of a polyethyleneglycol-polypropyleneglycol-polyethyleneglycol (PEG-PPG-PEG) block copolymer having a polyethyleneglycol (PEG) content of 65-85 wt % and a molecular weight of 6 ,000-20 ,000 Da; 0.03-5 wt % gelatin; 0.03-5 wt % of chitosan; and distilled water.2. The anti-adhesion polymer composition of claim 1 , wherein the block copolymer is composed of two kinds of block copolymers having different PEG contents.3. The anti-adhesion polymer composition of claim 2 , wherein the cont or each of the block copolymers in the composition is 12-25 wt %.4. The anti-adhesion polymer composition of claim 1 , further comprising glycerol as a stabilizer for suppressing phase separation of the composition.5. The anti-adhesion polymer composition of claim 1 , further comprising at least one growth factor selected from among epidermal growth factor (EGF claim 1 , beta-urogastrone) claim 1 , heparin-binding EGF-like growth factor (HB-EGF) claim 1 , transforming growth factor-α (TGF-α) and fibroblast growth factors (FGFs). The present invention relates to an anti- ...

Adhesive Composition

The invention is directed to an adhesive complex coacervate composition, to a method of physically crosslinking an adhesive complex coacervate composition, to a method for adhering a tissue defect in a subject, and to the use of an adhesive complex coacervate composition. The adhesive complex coacervate composition of the invention comprises a polycation and a polyanion, wherein said polycation and polyanion together comprise on average at least two thermoresponsive moieties per polymer chain, said thermoresponsive moieties exhibiting a lower critical solution temperature, wherein said polycation comprises 5-70 mol % of thermoresponsive moieties and/or wherein said polyanion comprises 5-70 mol % of thermoresponsive moieties, and wherein said polycation and/or said polyanion is a graft or block copolymer comprising said thermoresponsive moieties.

Method for Preparing Modified Sodium Alginate Embolization Microsphere

The present invention relates to a preparation method for modified sodium alginate embolization microspheres and a method for carrying an anti-cancer drug doxorubicin by means of modified sodium alginate embolization microspheres. The preparation method includes the following steps: (1) sodium alginate is modified by using taurine, so that modified sodium alginate is synthesized; (2) with high-concentration aqueous modified sodium alginate solution as a water phase, mineral oil as an oil phase and polyaldehyde cellulose as a crosslinking agent, modified sodium alginate embolization microspheres are prepared by an inverse emulsification method. By modifying sodium alginate by means of taurine, on one hand, sulfonic acid groups are introduced into the embolization microspheres, so that the drug-carrying rate is increased; on the other hand, the viscosity of a sodium alginate solution is decreased, which is favorable for the preparation of the high-concentration sodium alginate solution, and thereby regular sodium alginate embolization microspheres can be obtained.

Intervertebral fusion device comprising an intervertebral stabilising screw and a composition for bone remodelling

The invention relates to an intervertebral fusion device comprising an intervertebral stabilizing screw and a composition for bone remodeling. The intervertebral stabilizing screw comprises: a main body with an axial through-hole and a distal thread that is secured to the bone, located at a distal end of the main body; a hollow proximal secondary body that can slide along the length of the main body; and a travel stop for the proximal secondary body, located on an outer surface of the main body. According to the invention, the proximal secondary body also includes an external thread for securing to the bone, and the main body comprises at least one fill hole, located between the distal thread and the travel stop, for connecting an intervertebral space to the aforementioned axial hole.

LIQUID EMBOLIC AGENT COMPOSITION

Provided is a liquid embolic agent composition capable of solving problems of conventional embolic agents, which can be used in a treatment of a vascular disease such as cerebral aneurysm. The problems are solved by a liquid embolic agent composition characterized in containing a hydrogel forming component having a calcium ion entrapping ability, and an anti-biodegradation component. The hydrogel forming component having a calcium ion entrapping ability is at least one kind of acidic polysaccharide selected from the group consisting of alginate, gellan gum, carrageenan, and carboxymethyl cellulose salt; and the anti-biodegradation component is at least one kind selected from the group consisting of hydroxypropyl methylcellulose, methylcellulose, polyvinyl alcohol, polyallylamine, poly-N-vinyl acetamide, and cellulose acetate. 19-. (canceled)10. A liquid embolic agent composition which comprises:a hydrogel forming component having a calcium ion entrapping ability; andan anti-biodegradable component,wherein the hydrogel forming component having a calcium ion entrapping ability comprises sodium alginate and gellan gum,wherein the anti-biodegradable component is hydroxypropyl cellulose, andwherein the liquid embolic agent composition is in a liquid state in vitro, and gelates by reacting with calcium ions in blood to exhibit a bioadhesiveness in vivo.11. The liquid embolic agent composition according to claim 10 , further comprising a coagulation promoting component claim 10 , wherein the coagulation promoting component is at least one selected from the group consisting of colloidal silica claim 10 , poly(N claim 10 ,N-dimethyl) acrylamide claim 10 , an enzyme preparation for food processing claim 10 , poly-L-lysine hydrobromide claim 10 , poly-L-glutamic acid sodium salt claim 10 , chitosan claim 10 , and silk fibroin.12. The liquid embolic agent composition according to claim 10 , which is used for treating cerebral aneurysm.13. The liquid embolic agent composition ...

METHODS AND COMPOSITIONS COMPRISING BIODEGRADABLE CYANOACRYLATES

Disclosed herein are methods of making and using cyanoacrylate compositions comprising one or more cyanoacrylates, a high level of at least one stabilizing agent and at least one free-radical polymerization inhibitor. Methods disclosed comprise making such compositions and using such compositions, for example, for occluding conduits such as fallopian tubes. 1. A biodegradable cyanoacrylate composition , comprising ,a) a cyanoacrylate component comprising at least one cyanoacrylate, wherein the cyanoacrylate component is 80 wt % or greater;b) a stabilizer component in a range from 500 ppm to 1500 ppm; andc) a polymerization inhibitor component in a range from 4000 to 7000 ppm.2. The biodegradable cyanoacrylate composition of claim 1 , wherein the cyanoacrylate component comprises at least two cyanoacrylate monomers.3. The biodegradable cyanoacrylate composition of claim 1 , wherein the cyanoacrylate monomer is methyl cyanoacrylate claim 1 , ethyl cyanoacrylate claim 1 , propyl cyanoacrylate claim 1 , butyl cyanoacrylate claim 1 , pentyl cyanoacrylate claim 1 , hexyl cyanoacrylate claim 1 , septyl cyanoacrylate claim 1 , octyl nonyl cyanoacrylate claim 1 , decyl 2-cyanoacrylate claim 1 , allyl cyanoacrylate claim 1 , methoxyethyl cyanoacrylate claim 1 , methoxyisopropyl cyanoacrylate claim 1 , methoxypropyl cyanoacrylate claim 1 , methoxybutyl cyanoacrylate claim 1 , methoxypentyl cyanoacrylate claim 1 , or combinations thereof.4. The biodegradable cyanoacrylate composition of claim 1 , wherein the stabilizer component comprises an alkyl sulfide claim 1 , alkyl sulfate claim 1 , alkyl sulfonyl claim 1 , alkyl sulfone claim 1 , alkyl sulfoxide claim 1 , alkyl sulfite claim 1 , sultone claim 1 , sulfur dioxide claim 1 , sulfur trioxide claim 1 , sulfonic acid claim 1 , lactone claim 1 , boron trifluoride claim 1 , acetic acid claim 1 , or 3-sulfolene claim 1 , mercaptan claim 1 , or combinations thereof.5. The biodegradable cyanoacrylate composition of claim 4 , wherein ...

STABLE COMPOSITIONS COMPOSED OF A RADIOPAQUE AGENT AND CYANOACRYLATE MONOMER AND APPLICATIONS THEREOF

Described herein are compositions composed of a radiopaque agent and a cyanoacrylate monomer. These compositions cure in situ when administered to a subject and, thus, have numerous biomedical applications. The presence of the radiopaque agent allows the practitioner to visualize the compositions during and immediately after administration to the subject. The compositions are non-toxic and shelf-stable, and can be sterilized to prevent microbial growth. The compositions can be pre-mixed prior to sale and distribution, reducing the need for special training in their use. 2. The composition of claim 1 , wherein the radiopaque agent comprises two groups comprising the structure I.4. The composition of claim 3 , wherein Rand Rare the same alkyl group.5. The composition of claim 4 , wherein Rand Rare each a Cto Calkyl group.6. The composition of claim 4 , wherein Rand Rare each methyl claim 4 , ethyl claim 4 , propyl claim 4 , butyl claim 4 , pentyl claim 4 , hexyl claim 4 , heptyl claim 4 , or octyl.7. The composition of claim 1 , wherein the cyanoacrylate monomer is an alkyl cyanoacrylate monomer claim 1 , a cycloalkyl cyanoacrylate monomer claim 1 , an allyl cyanoacrylate monomer claim 1 , an aryl cyanoacrylate monomer claim 1 , an aralkyl cyanoacrylate monomer claim 1 , a carboxy alkyl cyanoacrylate monomer or an iodo-substituted cyanoacrylate monomer.8. The composition of claim 1 , wherein the cyanoacrylate monomer is a C-Calkyl cyanoacrylate monomer.9. The composition of claim 1 , wherein the alkyl cyanoacrylate monomer is butyl cyanoacrylate monomer.10. The composition of claim 3 , wherein the cyanoacrylate monomer is butyl cyanoacrylate monomer and Rand Rare the same alkyl group.11. The composition of claim 10 , wherein Rand Rare each methyl claim 10 , ethyl claim 10 , propyl claim 10 , butyl claim 10 , pentyl claim 10 , heptyl claim 10 , or octyl.12. The composition of claim 1 , wherein the cyanoacrylate monomer is from 30 wt % to 90 wt % of the composition.13. ...

NOVEL BIODEGRADABLE BONE PLATES AND BONDING SYSTEMS

The invention relates to novel internal fixation devices, such as bone plates, generally and novel craniomaxillofacial bone plates more specifically and systems for bonding the same. More specifically, the invention relates to bone plates made of a polymer blend of (poly)lactic acid and Ecoflex as well as a novel hot-melt adhesive polymer blend of the same material .

Spinal disk regenerative composition and method of manufacture and use

The present invention provides a novel way to replenish the disc using retooled disc compositions to repair degenerative discs. There is no better source of proteoglycans than the actual disc material ( 6 ) itself. To this end, there has been developed a technique to remove the nucleus pulposus and retool the morphology of the nucleus pulposus to create a powder material ( 10 ) that is dry and can be stored at room temperature for long periods of time. This powder ( 10 ) can then be reconstituted with a variety of fluids, the most suitable being normal saline or lactated ringers to form a flowable mixture ( 20 ).

METHOD OF MAKING INJECTABLE CEMENTS

A discovery of the conversion of amorphous calcium polyphosphate (ACPP) or/and other polyphosphate salts with various type of calcium phosphate to new calcium phosphate product (i.e. dicalcium phosphate dihydrate (DCPD)) in a liquid environment. The discovery includes mixing a various type of calcium phosphate with an aqueous ACPP or/and other polyphosphate salts gel, which is fast setting and possessing strong mechanical strength, and can be gradually converted to DCPD/hydroxyapatites in physiological condition. This injectable past can be applied as alternative of conventional CPC bone cement that is suitable for bone void repair due to its excellent properties in osteoconductivity and osseointegration. It can also be applied as drug delivery device in tissue engineering for its strong bonding to drug molecules. 1. A cement comprising:a first compound comprising a hydrogel including a polyphosphate, anda second compound comprising calcium and phosphate,wherein the cement is injectable and has a mechanical strength for a bone repair application.2. The cement of claim 1 , wherein the cement has a setting mechanism comprising reaction of dehydration of the hydrogel.3. The cement of wherein the second compound comprises at least one of sodium polyphosphate claim 1 , potassium polyphosphate claim 1 , calcium polyphosphate claim 1 , strontium polyphosphate claim 1 , magnesium polyphosphate claim 1 , aluminum polyphosphate claim 1 , zinc polyphosphate claim 1 , copper polyphosphate claim 1 , cadmium polyphosphate claim 1 , manganese polyphosphate claim 1 , ammonium polyphosphate claim 1 , and a chelated polyphosphate including composites and blends thereof.4. The cement of wherein the polyphosphate has a degree of polymerization of at least about 2.5. The cement of wherein the mechanical strength comprises a compressive strength of between about 5 megapascal and about 200 megapascal.6. The cement of wherein the second compound comprises a calcium phosphate ceramic.7. The ...

Hydrocolloid Wound Dressings with Increased WVTR

Hydrocolloid compositions, wound dressings, methods of using such compositions and such wound dressings, and methods of forming such hydrocolloid compositions, wherein the hydrocolloid compositions include a hydrophobic, unsaturated, elastomeric polymer; a hydrocolloid absorbent; and a hydrophilic polymer including an unsaturated polymer backbone having polyalkylene ether groups bonded thereto. 1. A hydrocolloid composition comprising:a hydrophobic, unsaturated, elastomeric polymer;a hydrocolloid absorbent; anda hydrophilic polymer comprising an unsaturated polymer backbone having polyalkylene ether groups bonded thereto, wherein the hydrophilic polymer is present in an amount that increases the WVTR of the hydrocolloid composition relative to the same hydrocolloid composition without the hydrophilic polymer.2. The hydrocolloid composition of wherein the hydrophobic and hydrophilic polymers are crosslinked to provide the composition with a crosslinked matrix comprising partial unsaturation.3. The hydrocolloid composition of which is in the form of an adhesive.4. The hydrocolloid composition of which is in the form of a pressure sensitive adhesive.5. (canceled)6. The hydrocolloid composition of wherein the hydrophobic claim 1 , unsaturated claim 1 , elastomeric polymer is present in an amount of 20-50 wt-% claim 1 , based on the total weight of the composition.7. The hydrocolloid composition of wherein the hydrophilic polymer is present in an amount of 0.5-20 wt-% claim 1 , based on the total weight of the composition.8. The hydrocolloid composition of wherein the hydrocolloid absorbent is present in an amount of 5-60 wt-% claim 1 , based on the total weight of the composition.9. The hydrocolloid composition of wherein the polyalkylene ether groups are derived from a hydrophilic polyalkylene oxide-containing compound.10. The hydrocolloid composition of wherein the hydrophilic polyalkylene oxide-containing compound comprises ethylene oxide units and optionally co- ...

SURGICAL METHODS EMPLOYING PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS

Compositions, methods and delivery devices (e.g., pre-filled syringes) for controlling bleeding during surgical procedures are provided, wherein the compositions are characterized as having an aqueous formulation that is capable of adopting a gelled state upon contact with bodily fluids and/or blood of a patient (i.e., physiological conditions).

VITAMIN E PHOSPHATE OR ACETATE FOR USE IN THE TREATMENT AND PREVENTION OF BIOFILM INFECTIONS

The present invention concerns vitamin E selected among vitamin E phosphate, optionally in combination with methylene blue, and/or vitamin E acetate in combination with methylene blue for use in the treatment and prevention of biofilm infections or as an antifungal agent by means of the application of vitamin E as defined above or in combination with a biocompatible vector on inert or living surfaces. 118-. (canceled)19. Vitamin E for use in the treatment and prevention of biofilm infections , such as bacterial or fungal biofilm , wherein the vitamin E is selected from the group consisting of vitamin E phosphate , optionally in combination with methylene blue , and/or vitamin E , such as vitamin E acetate , in combination with methylene blue.20Escherichia coliPseudomonas aeruginosaStaphylococcus aureusStaphylococcus epidermidisCandida albicans. Vitamin E according to claim 19 , wherein the biofilm is a gram-negative bacterial biofilm claim 19 , such as biofilms formed by and claim 19 , a gram-positive bacterial biofilm containing bacteria such as biofilms formed by and claim 19 , or a fungal biofilm such as a biofilm formed by for example.21. Vitamin E according to claim 19 , wherein vitamin E phosphate and/or vitamin E such as vitamin E acetate for example is used at a concentration of up to 100 w/v % claim 19 , preferably ranging from 1 to 50 w/v % and even more preferably from 5 to 20 w/v %.22. Vitamin E according to claim 19 , wherein the vitamin E is applied on living surfaces such as surfaces of wounds claim 19 , of the skin claim 19 , joints claim 19 , bones claim 19 , and of internal tissues for example.23. Use of vitamin E as defined in against the formation of a biofilm on inert surfaces by applying said vitamin E on to the inert surfaces claim 19 , such as on the surfaces of prostheses or implantable biomaterials claim 19 , of material for osteosynthesis and fracture fixation claim 19 , of catheters or endovascular devices claim 19 , bone cements claim 19 ...

WATER-RICH ADHERENT GEL, COMPOSITION FOR MANUFACTURING WATER-RICH ADHERENT GEL, AND ELECTRODE PAD

The present invention provides an adhesive, high water content gel that does not cause about generation problem even when used as a patient plate for electrosurgical units through which high current flows and that is excellent adhesion, as well as an electrode pad including the gel. The present invention relates to an adhesive, high water content hydrogel containing a polymer matrix that includes a copolymer of a polymerizable monomer and a crosslinkable monomer, water, a polyhydric alcohol, an electrolyte, polyacrylic acid, and polyvinyl alcohol, the hydrogel containing, based on 100% by weight of the total hydrogel, 40-70% by weight of water, 1.0-5.0% by weight of polyacrylic acid, and 0.5-5.0% by weight of polyvinyl alcohol, and being produced by copolymerization. An electrode pad is also obtained by coating a conductive layer formed on a base film with the adhesive, high water content hydrogel. 1. An adhesive , high water content hydrogel , comprising:a polymer matrix comprising a copolymer of a polymerizable monomer and a crosslinkable monomer;water;a polyhydric alcohol;an electrolyte;polyacrylic acid; andpolyvinyl alcohol,the hydrogel comprising, based on 100% by weight of the total hydrogel, 40% to 70% by weight of water, 1.0% to 5.0% by weight of polyacrylic acid, and 0.5% to 5.0% by weight of polyvinyl alcohol.2. The adhesive claim 1 , high water content hydrogel according to claim 1 ,wherein the polymer matrix is produced by copolymerization using an amphiphilic monomer as part of the polymerizable monomer in an amount of 0.5% to 5.0% by weight based on 100% by weight of the total hydrogel.3. The adhesive claim 2 , high water content hydrogel according to claim 2 ,wherein the amphiphilic monomer is N,N-dimethyl(meth)acrylamide.4. The adhesive claim 1 , high water content hydrogel according to claim 1 ,wherein the hydrogel comprises 45% to 65% by weight of water.5. The adhesive claim 1 , high water content hydrogel according to claim 1 ,wherein the ...

EMBOLIC MICROSPHERES

In some aspects, the disclosure pertains to injectable particles that contain at least one pH-altering agent that is configured to be released from the injectable particles in vivo, upon embolization of an intratumoral artery of a tumor with the injectable particles. In certain instances, the pH-altering agent may be a basic agent having a pH value of 7.5, a buffering agent having a pKa value of 7.6 or more, or both. Other aspects of the disclosure pertain to preloaded containers containing such injectable particles and methods of using such injectable particles. 1. Injectable particles comprising at least one pH-altering agent that is configured to be released from the injectable particles in vivo upon embolization of an intratumoral artery of a tumor with the injectable particles.2. The injectable particles of claim 1 , wherein the injectable particles are configured such that claim 1 , upon embolization of the intratumoral artery of the tumor with the injectable particles claim 1 , the injectable particles release the pH-altering agent such that a microenvironment is created in a vascular bed of the tumor downstream of the injectable particles that has a pH that is higher than a pH that would otherwise exist in the absence of the pH-altering agent.3. The injectable particles of claim 1 , wherein the injectable particles are spherical or non-spherical particles.4. The injectable particles of claim 1 , wherein the injectable particles range from 20 to 1500 microns in diameter.5. The injectable particles of claim 1 , wherein the pH-altering agent is (a) a basic agent having a pH value of 7.5 or more claim 1 , (b) a buffering agent having a pKa value of 7.6 or more claim 1 , or a combination of (a) and (b).6. The injectable particles of claim 1 , wherein the pH-altering agent is (a) a basic agent having a pH value ranging from 7.5 to 10 claim 1 , (b) a buffering agent having a pKa value ranging from 8 to 35 claim 1 , or (c) a combination of (a) and (b).7. The ...

Dry Composition Comprising An Extrusion Enhancer

Disclosed is a dry composition comprising one or more polyols, which upon addition of an aqueous medium forms a substantially homogenous paste suitable for use in haemostasis procedures. The paste reconstitutes spontaneously upon addition of the liquid; hence no mechanical mixing is required for said paste to form. The composition may further comprise an extrusion enhancer, such as albumin. Also disclosed are methods of preparing said dry composition, a paste obtained from said dry composition and uses of said dry composition or paste for medical and surgical purposes. 1. A dry composition suitable for use in haemostasis and wound healing comprising a frozen paste that has been freeze-dried , said dry composition comprising a biocompatible polymer , an extrusion enhancer and one or more polyols , wherein the dry composition is obtained by the method comprising sequentially:a) providing a cross-linked biocompatible polymer in powder form, one or more polyols selected from sugar alcohols or sugars, an extrusion enhancer and an aqueous medium;b) mixing the biocompatible polymer, the one or more polyols, the extrusion enhancer and the aqueous medium to obtain a paste; and 'wherein the dry composition comprises from about 10% w/w to about 60% w/w of the one or more polyols, and wherein upon addition of an aqueous medium, the dry composition reconstitutes to form a paste without mechanical mixing.', 'c) freeze-drying the paste,'}2. The dry composition according to claim 1 , wherein the extrusion enhancer is selected from albumin claim 1 , phosphatidylcholine claim 1 , phosphatidylserine claim 1 , lecithin or soy bean oil.3. The dry composition according to claim 1 , wherein the dry composition comprises from about 0.3% w/w to about 30% w/w of the extrusion enhancer.4. The dry composition according to claim 1 , wherein the biocompatible polymer is obtained from a cross-linked sponge.5. The dry composition according to claim 1 , wherein the biocompatible polymer is gelatine ...

Hip Joint method

A surgical or arthroscopic method for resurfacing at least one surface of a hip joint of a human patient, using a medical device comprising an artificial hip joint surface, wherein the hip joint surface comprising an acetabulum surface and a caput femur surface, said method comprising the steps of: creating at least one hole passing into the hip joint, dissecting and preparing the hip joint, introducing at least one artificial hip joint surface, comprising at least one of an artificial acetabulum surface and an artificial caput femur surface, wherein said at least one artificial hip joint surface, comprising a first sealing member, creating a sealed hollow space between said first sealing member and one of the acetabulum surface or said artificial acetabulum surface and one of the caput femur surface or said artificial caput femur surface, selecting at least one artificial hip joint surface and injecting a material into said hollow space. 152-. (canceled)55. A surgical or arthroscopic method for resurfacing at least one surface of a hip joint of a human patient , using a medical device comprising an artificial hip joint surface , wherein the hip joint surface comprising an acetabulum surface and a caput femur surface , said method comprising the steps of:creating at least one hole passing into the hip joint,dissecting and preparing the hip joint,introducing at least one artificial hip joint surface, comprising at least one of an artificial acetabulum surface and an artificial caput femur surface, wherein said at least one artificial hip joint surface, comprising a first sealing member,creating a sealed hollow space between said first sealing member and one of the acetabulum surface or said artificial acetabulum surface and one of the caput femur surface or said artificial caput femur surface, selecting at least one artificial hip joint surface,injecting a material into said hollow space.56. A surgical or arthroscopic method according to claim 55 , wherein said at ...

Method of forming and using a hemostatic hydrocolloid

A method and system for forming a hemostatic hydrocolloid for dispensing into a wound site includes a polymer of oxidized derivatized esterified cellulose in solid form comprising a chain of monomers, wherein, for a first plurality of the monomers in the chain: R is —OCH 2 (COO)CH 2 CH 3 , R1 is —OCH 2 (COO)CH 2 CH 3 , and R2 is —CH 2 OCH 2 (COO)CH 2 CH 3 ; and wherein, for a second plurality of monomers in the chain: R is —OCH 2 (COO)CH 2 CH 3 , R1 is —OCH 2 (COO)CH 2 CH 3 , and R2 is —(COO)CH 2 CH 3 and a liquid mixed with the polymer to form a hemostatic gel for dispensing into a wound site.

Antimicrobial Adhesives Having Improved Properties

Adhesive compositions exhibiting antimicrobial properties, good stability, long shelf lives and enhanced release of antimicrobial agents are described. In certain versions, the compositions also exhibit relatively high fluid handling capacities. The adhesive compositions inhibit microbial growth by more than 2 log after 24 hours contact and particularly more than 3.5 log after 6 hours contact. Also described are various medical articles using such adhesives and related methods. 1. An antimicrobial adhesive composition comprising chlorhexidine and at least one non-gelling disintegrant;wherein the adhesive composition inhibits microbial growth by more than 2 log throughout a 7-day contact time period;wherein at least one non-gelling disintegrant is microcrystalline cellulose; andwherein the non-gelling disintegrant is 15% to 45% of the antimicrobial adhesive composition.2. The adhesive composition of wherein the adhesive composition exhibits a static absorption of at least about 5 g/m2/24 hours.3. The adhesive composition of wherein the adhesive composition also exhibits a moisture vapor transmission rate (MVTR) of at least 400 g/m2/24 hours.5. The medical article of wherein the adhesive composition exhibits a static absorption of at least about 5 g/m2/24 hours.6. The medical article of wherein the adhesive composition also exhibits a moisture vapor transmission rate (MVTR) of at least 400 g/m2/24 hours.8. The adhesive composition of wherein the adhesive composition is a pressure sensitive adhesive.9. The adhesive composition of wherein the adhesive component comprises an acrylic-based adhesive.10. The adhesive composition of wherein the adhesive component comprises a silicone-based adhesive.11. The adhesive composition of wherein the adhesive component comprises a rubber-based adhesive.12. The adhesive composition of wherein the adhesive component comprises a polyurethane-based adhesive.13. The adhesive composition of further comprising at least one agent selected ...

Minced Cartilage Systems and Methods

Compositions comprising a plurality of cartilage particles from a human adult cadaveric donor, wherein the cartilage particles comprise viable chondrocytes, and a biocompatible carrier are provided. Methods of manufacturing cartilage compositions comprising a plurality of cartilage particles from a human adult cadaveric donor are also provided.

BIOADHESIVE HYDROGELS

A bioadhesive includes a crosslinked biodegradable hydrogel that includes a plurality of oxidized, acrylated or methacrylated, natural polymer. Bioadhesives are natural or synthetic materials that can be used for soft tissue repair to create a seal preventing leakage of biological fluids or to reinforce anatomic integrity as an attractive alternative to sutures and staples. The most widely used bioadhesives are fibrin, cyanoacrylates, and albumin-glutaraldehyde bioadhesives. 1. A bioadhesive comprising: a crosslinked biodegradable hydrogel that includes a plurality of oxidized , acrylated or methacrylated , natural polymer macromers crosslinked with a plurality of branched poly(ethylene glycol) macromers.2. The bioadhesive of claim 1 , wherein the oxidized claim 1 , acrylated or methacrylated claim 1 , natural polymer macromers include a plurality of aldehyde groups that are crosslinked with the branched poly(ethylene glycol) macromers.3. The bioadhesive of claim 1 , wherein the oxidized claim 1 , acrylated or methacrylated claim 1 , natural polymer macromers are polysaccharides claim 1 , which are oxidized so that about 1% to about 50% of the saccharide units therein are converted to aldehyde saccharide units.4. The bioadhesive of claim 1 , wherein acrylate or methacrylate groups of the natural polymer macromers are crosslinked so that the hydrogel is dual crosslinked.5. The bioadhesive of claim 1 , the oxidized claim 1 , acrylated or methacrylated claim 1 , natural polymer macromers comprising oxidized claim 1 , acrylated or methacrylated claim 1 , alginates.6. The bioadhesive of claim 1 , wherein the poly(ethylene glycol) macromers are poly(ethylene glycol) amine macromers.7. The bioadhesive of claim 6 , wherein the poly(ethylene glycol) amine macromers are n-arm poly(ethylene glycol) amines claim 6 , where n is an integer greater than 1.8. The bioadhesive of claim 1 , wherein the hydrogel is cytocompatible and claim 1 , upon degradation claim 1 , produces ...

Tiny Bone Defect Repairing Material, Matrix Material Thereof and Producing Method Thereof

The present invention provides a producing method for a tiny bone defect repairing material. The invention solves the problems that the setting time is too long to cause bad mechanical property in conventional bone cements and also remains bioactivities and water absorb ability. The invention has no cytotoxicity and enables to stimulate cells growth.

BIMODAL TREATMENT METHODS AND COMPOSITIONS FOR GASTROINTESTINAL LESIONS WITH ACTIVE BLEEDING

The present invention relates to a long-lasting medical product for protecting or treating a lesion in the gastrointestinal tract. The medical product includes a protective covering, wherein the medical product upon application at and about the site of the lesion adheres to the gastrointestinal tissue and is capable of remaining at and about the site of the lesion for a time sufficient to allow the lesion to heal or be treated. 120-. (canceled)21. A method for protecting and treating a lesion with active bleeding in the gastrointestinal tract , comprising:directly applying a hemostatic composition comprising a hemostatic agent at and about a site of the lesion in the gastrointestinal tract in the amount and for a time sufficient to stop the active bleeding; andonce the active bleeding has stopped or slowed, directly applying a protective covering comprising an adhesive agent on top of and about at least a portion of the previously applied hemostatic composition, wherein the protective covering upon application on top of and about at least a portion of the hemostatic composition is in direct contact with both the hemostatic composition and tissue surrounding the lesion, provides a sustained protective barrier, and is capable of remaining at and about the site of the lesion for a minimum of 30 minutes.22. The method of claim 21 , wherein the step of applying the hemostatic composition comprises spraying claim 21 , ejecting or spreading the hemostatic agent at and about the site of the lesion with the active bleeding.23. The method of claim 21 , wherein the step of applying the protective covering comprises spraying claim 21 , ejecting or spreading the protective covering on top of and about at least a portion of the previously applied hemostatic composition at and about the lesion site in the gastrointestinal tract.24. The method of claim 21 , wherein the adhesive agent is in a powder claim 21 , a liquid or a gel form.25. The method of claim 21 , wherein the adhesive ...

Ostomy device

Disclosed is an ostomy device with an adhesive wafer for attachment to a skin surface (S) of a user and a collecting bag () or collecting output from a stoma. The collecting bag is connected to the adhesive wafer, and the adhesive wafer has a through-going hole () for accommodating the stoma () of the user. The adhesive wafer includes a backing layer (), a first switchable adhesive composition (), a second absorbent adhesive composition (), and a release liner, and the second adhesive layer has a central portion with a first thickness and an edge portion with a second thickness, the first thickness being larger than the second thickness. 125.-. (canceled)26. An ostomy device providing a hole adapted for placement around a stoma of a user , the ostomy device comprising:an adhesive wafer having a backing layer, a switchable adhesive layer applied to the backing layer, and an absorbent adhesive layer applied to the switchable adhesive layer, where the backing layer defines a distal surface of the ostomy device and is adapted to receive a collecting bag for collection of output from the stoma;wherein the hole is formed through the backing layer, the absorbent adhesive layer, and the switchable adhesive layer;wherein the switchable adhesive layer is a ring-shaped annular band having a lateral extent that extends from an edge of the hole to an outermost perimeter of the ostomy device and the absorbent adhesive layer is formed around an entirety of the hole and extends from the edge of the hole to a rim that is located a radial distance away from the edge of the hole, where the radial distance is less than the outermost perimeter of the ostomy device;wherein the absorbent adhesive layer has a first thickness measured at the edge of the hole and a second thickness measured at the rim, and the first thickness is larger than the second thickness;wherein the switchable adhesive layer comprises a photoinitiator reactive to visible light;wherein the absorbent adhesive layer ...

Synthetic mechanical hemostatic composition, method of making and use thereof

A biocompatible, polymeric composition is disclosed. The composition comprises a base polymer comprising (i) a prepolymer comprising para-dioxanone (PDO) and trimethylene carbonate (TMC); and (ii) an end-graft polymer chain comprising a polylactone. Also disclosed are a method for treating bleeding from bone or bony structures using the composition, a method for filling a void or correct a defect in a bone using the composition, and a method for producing the biocompatible, polymeric composition of the present application.

ULTRA-LIGHT WEIGHT HEMOSTATIC MICROSPHERES

A hemostatic composition comprises a powder of a plurality of hollow or highly-porous microparticles that exhibit hemostatic properties, wherein each of the microparticles comprise a body comprising a clay material that is a crystalline hydrated form of a layered silicate. 1. A hemostatic composition comprising:a powder comprising a plurality of hollow or highly-porous microparticles that exhibit hemostatic properties, wherein each of the microparticles comprise a body comprising a clay material that is a crystalline hydrated form of a layered silicate.2. A hemostatic composition according to claim 1 , wherein the clay material comprises hectorite claim 1 , laponite claim 1 , kaolinite claim 1 , bentonite claim 1 , montmorillonite claim 1 , saponite claim 1 , hectorite claim 1 , palygorskite claim 1 , sepiolite or combinations thereof.3. A hemostatic composition according to claim 1 , wherein the plurality of microparticles have a specific surface area of at least about 75 square meters per gram.4. (canceled)5. (canceled)6. A hemostatic composition according to claim 1 , wherein the powder has a density claim 1 , when uncompacted claim 1 , of from about 0.006 grams per cubic centimeter to about 0.009 grams per cubic centimeter.7. A hemostatic composition according to claim 1 , wherein at least a portion of the microparticles have a size in a largest dimension of less than or equal to 500 micrometers.8. (canceled)9. (canceled)10. A hemostatic composition according to claim 1 , wherein at least a portion of the microparticles have a size in a largest dimension of from about 50 micrometers to about 200 micrometers.11. A hemostatic composition according to claim 1 , wherein at least a portion of the microparticles comprise a porous structure with a plurality of pores formed in the microparticles claim 1 , wherein each of the plurality of pores have a size of from about 1 micrometer to about 10 micrometers.1216-. (canceled)17. A hemostatic composition according to claim ...

Photoactivated crosslinking of a protein or peptide

A method of crosslinking a protein or peptide for use as a biomaterial, the method comprising the step of irradiating a photoactivatable metal-ligand complex and an electron acceptor in the presence of the protein or peptide, thereby initiating a cross-linking reaction to form a 3-dimensional matrix of the biomaterial.

Sealing agent for genitals

The present invention aims to provide a cervical canal sealant that can be used as a sealant to stop bleeding in the uterus and vaginal discharge, particularly, a cervical canal sealant that can block the cervical canal to inhibit amniotic fluid leakage and that can also be peeled off without damaging reproductive tissue. The present invention relates to a sealant for reproductive organs in which a cured product (X) at 25° C. has a storage modulus G′ of 200 to 2,000 kPa, the cured product (X) being a cured product obtained by curing the sealant for reproductive organs to a thickness of 120 to 150 μm.

Polymeric treatment compositions

Polymeric compositions are described comprising a biocompatible polymer including a biodegradable linkage to a visualization agent and a non-physiological pH solution; wherein the biocompatible polymer is soluble in the non-physiological pH solution and insoluble at a physiological pH. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use.